<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism - Robertson, L - 2017 | Cochrane Library</title> <meta content="Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism - Robertson, L - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001100.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism - Robertson, L - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001100.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001100.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism" name="citation_title"/> <meta content="Lindsay Robertson" name="citation_author"/> <meta content="Freeman Hospital" name="citation_author_institution"/> <meta content="lindsay.robertson@nuth.nhs.uk" name="citation_author_email"/> <meta content="Lauren E Jones" name="citation_author"/> <meta content="Freeman Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD001100.pub4" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/02/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001100.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001100.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001100.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticoagulants [*administration &amp; dosage, adverse effects]; Hemorrhage [chemically induced]; Heparin [administration &amp; dosage, adverse effects]; Heparin, Low‐Molecular‐Weight [*administration &amp; dosage, adverse effects]; Injections, Subcutaneous; Pulmonary Embolism [*drug therapy, mortality]; Randomized Controlled Trials as Topic; Recurrence; Venous Thrombosis [*drug therapy, mortality]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001100.pub4&amp;doi=10.1002/14651858.CD001100.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6zFwvAqw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001100\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001100\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001100\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001100\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001100.pub4",title:"Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism",firstPublishedDate:"Feb 9, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001100.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001100.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001100.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001100.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001100.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001100.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001100.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001100.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001100.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001100.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5589 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001100.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/full#CD001100-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/full#CD001100-sec-0082"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/full#CD001100-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/full#CD001100-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/full#CD001100-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/full#CD001100-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/full#CD001100-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/full#CD001100-sec-0076"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/appendices#CD001100-sec-0087"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/table_n/CD001100StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/table_n/CD001100StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/information#CD001100-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Lindsay Robertson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001100.pub4/information#CD001100-cr-0003">Lauren E Jones</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/information/en#CD001100-sec-0096">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 February 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001100.pub4">https://doi.org/10.1002/14651858.CD001100.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001100-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001100-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001100-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001100-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001100-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001100-abs-0001" lang="en"> <section id="CD001100-sec-0001"> <h3 class="title" id="CD001100-sec-0001">Background</h3> <p>Low molecular weight heparins (LMWHs) have been shown to be effective and safe in preventing venous thromboembolism (VTE). They may also be effective for the initial treatment of VTE. This is the third update of the Cochrane Review first published in 1999. </p> </section> <section id="CD001100-sec-0002"> <h3 class="title" id="CD001100-sec-0002">Objectives</h3> <p>To evaluate the efficacy and safety of fixed dose subcutaneous low molecular weight heparin compared to adjusted dose unfractionated heparin (intravenous or subcutaneous) for the initial treatment of people with venous thromboembolism (acute deep venous thrombosis or pulmonary embolism). </p> </section> <section id="CD001100-sec-0003"> <h3 class="title" id="CD001100-sec-0003">Search methods</h3> <p>For this update the Cochrane Vascular Information Specialist (CIS) searched the Cochrane Vascular Specialised Register (15 September 2016). In addition the CIS searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 8) in the Cochrane Library (searched 15 September 2016) and trials' registries. </p> </section> <section id="CD001100-sec-0004"> <h3 class="title" id="CD001100-sec-0004">Selection criteria</h3> <p>Randomised controlled trials comparing fixed dose subcutaneous LMWH with adjusted dose intravenous or subcutaneous unfractionated heparin (UFH) in people with VTE. </p> </section> <section id="CD001100-sec-0005"> <h3 class="title" id="CD001100-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials for inclusion, assessed for quality and extracted data. </p> </section> <section id="CD001100-sec-0006"> <h3 class="title" id="CD001100-sec-0006">Main results</h3> <p>Six studies were added to this update resulting in a total of 29 included studies (n = 10,390). The quality of the studies was downgraded as there was a risk of bias in some individual studies relating to risk of attrition and reporting bias; in addition several studies did not adequately report on the randomisation methods used nor on how the treatment allocation was concealed. </p> <p>During the initial treatment period, the incidence of recurrent venous thromboembolic events was lower in participants treated with LMWH than in participants treated with UFH (Peto odds ratio (OR) 0.69, 95% confidence intervals (CI) 0.49 to 0.98; 6238 participants; 18 studies; P = 0.04; moderate‐quality evidence). After a follow‐up of three months, the period in most of the studies for which oral anticoagulant therapy was given, the incidence of recurrent VTE was lower in participants treated with LMWH than in participants with UFH (Peto OR 0.71, 95% CI 0.56 to 0.90; 6661 participants; 16 studies; P = 0.005; moderate‐quality evidence). Furthermore, at the end of follow‐up, LMWH was associated with a lower rate of recurrent VTE than UFH (Peto OR 0.72, 95% CI 0.59 to 0.88; 9489 participants; 22 studies; P = 0.001; moderate‐quality evidence). LMWH was also associated with a reduction in thrombus size compared to UFH (Peto OR 0.71, 95% CI 0.61 to 0.82; 2909 participants; 16 studies; P &lt; 0.00001; low‐quality evidence), but there was moderate heterogeneity (I² = 56%). Major haemorrhages occurred less frequently in participants treated with LMWH than in those treated with UFH (Peto OR 0.69, 95% CI 0.50 to 0.95; 8780 participants; 25 studies; P = 0.02; moderate‐quality evidence). There was no difference in overall mortality between participants treated with LMWH and those treated with UFH (Peto OR 0.84, 95% CI 0.70 to 1.01; 9663 participants; 24 studies; P = 0.07; moderate‐quality evidence). </p> </section> <section id="CD001100-sec-0007"> <h3 class="title" id="CD001100-sec-0007">Authors' conclusions</h3> <p>This review presents moderate‐quality evidence that fixed dose LMWH reduced the incidence of recurrent thrombotic complications and occurrence of major haemorrhage during initial treatment; and low‐quality evidence that fixed dose LMWH reduced thrombus size when compared to UFH for the initial treatment of VTE. There was no difference in overall mortality between participants treated with LMWH and those treated with UFH (moderate‐quality evidence). The quality of the evidence was assessed using GRADE criteria and downgraded due to concerns over risk of bias in individual trials together with a lack of reporting on the randomisation and concealment of treatment allocation methods used. The quality of the evidence for reduction of thrombus size was further downgraded because of heterogeneity between studies. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001100-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001100-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001100-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001100-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001100-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001100-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001100-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001100-abs-0003" lang="en"> <h3>Fixed daily dose of a low molecular weight heparin compared with an adjusted dose of unfractionated heparin for treating blood clots in the deep veins </h3> <p>Background</p> <p>Venous thromboembolism (VTE) is a condition in which a blood clot forms in the deep veins of the leg or pelvis (DVT) or the clot travels in the blood and blocks a blood vessel in the lungs (pulmonary embolism (PE)). The chances of getting a VTE can be increased if people have risk factors such as previous clots, prolonged periods of immobility (such as travelling on aeroplanes or bed rest), cancer, exposure to oestrogens (pregnancy, oral contraceptives or hormone replacement therapy), trauma and blood disorders such as thrombophilia (abnormal blood clotting). People with a VTE are treated with an anticoagulant, which prevents further clots from forming. Heparin is an anticoagulant and comes in two forms: low molecular weight heparin (LMWH) or unfractionated heparin (UFH). UFH is an older drug and is given either intravenously or by injection. When administering UFH, clinicians have to monitor blood‐clotting factors carefully and adjust the dose, because of the variability of its effect. LMWH is given by subcutaneous injection once or twice a day and does not need to be monitored as closely as UFH.<br/> <br/> Study characteristics and key results </p> <p>This review included 29 randomised controlled trials involving 10,390 participants (current to September 2016), which compared LMWH or UFH for treating people with blood clots. Pooling the results of these trials showed that fewer participants treated with LMWH formed further blood clots and that fewer cases of bleeding occurred. Use of LMWH also reduced the size of the original blood clot when compared to the UFH group. There was no difference in number of deaths between participants treated with LMWH and those treated with UFH. </p> <p>Quality of the evidence</p> <p>Results of this review indicate that LMWH may prevent further blood clots and bleeding in people with VTE. However, these findings must be interpreted with caution due to the moderate quality of the evidence as a result of lack of reporting of study methods and problems with study design. Results indicating reduced size of blood clots when taking LMWH also must be interpreted with caution due to the low quality of evidence as results were not similar across the studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001100-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001100-sec-0082"></div> <h3 class="title" id="CD001100-sec-0083">Implications for practice</h3> <section id="CD001100-sec-0083"> <p>This review presents moderate‐quality evidence that fixed dose LMWH reduced the incidence of recurrent thrombotic complications and occurrence of major haemorrhage during initial treatment and low‐quality evidence that fixed dose LMWH reduced thrombus size when compared to UFH for the initial treatment of VTE. There was no difference in overall mortality between participants treated with LMWH and those treated with UFH (moderate‐quality evidence). </p> </section> <h3 class="title" id="CD001100-sec-0084">Implications for research</h3> <section id="CD001100-sec-0084"> <p>Further studies are required to compare LMWH with UFH in the treatment of people with pulmonary embolism. In addition, a large RCT of at least two years' duration should be performed to determine the effects of dosing frequency on long‐term sequelae of venous thromboembolism, such as the development of post‐thrombotic syndrome. Individual low molecular weight heparin preparations could be compared with each other and new drugs should now be compared with LMWH. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001100-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001100-sec-0022"></div> <div class="table" id="CD001100-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">LMWH compared to UFH for initial treatment of venous thromboembolism</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>LMWH compared to UFH for initial treatment of venous thromboembolism</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with venous thromboembolism (VTE)<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> Low molecular weight heparin (LMWH)<br/> <b>Comparison:</b> Unfractionated heparin (UFH) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with UFH</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with LMWH</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of recurrent VTE<sup>1</sup> after </p> <p>initial treatment (up to 15 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.69<br/> (0.49 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6238<br/> (18 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000<br/> (12 to 24) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of recurrent VTE<sup>1</sup> </p> <p>(3 months follow‐up)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>OR 0.71<br/> (0.56 to 0.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>6661<br/> (16 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>51 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>37 per 1000<br/> (29 to 46) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of recurrent VTE<sup>1</sup> </p> <p>(end of follow‐up)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.72<br/> (0.59 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9489<br/> (22 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/> (30 to 44) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Reduction in thrombus size</p> <p>(pre‐ and post‐treatment venograms) <sup>5</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.71<br/> (0.61 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2909<br/> (16 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> LOW <sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>423 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>342 per 1000<br/> (309 to 375) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of major haemorrhagic episodes</p> <p>(during initial treatment ‐ up to 15 days) <sup>7</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.69<br/> (0.50 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8780<br/> (25 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/> (11 to 20) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall mortality</p> <p>(end of follow‐up)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.84<br/> (0.70 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9663<br/> (24 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000<br/> (41 to 57) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> for 'study population' was the average risk in the comparison groups (i.e. total number of participants with events in the control group divided by the number of participants in the comparison group). <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>LMWH</b> ; low molecular weight heparin; <b>RCTs</b> ; randomised controlled trials <b>OR:</b> Peto odds ratio; <b>UFH</b> : unfractionated heparin; <b>VTE</b>: venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Recurrent venous thromboembolism (VTE) defined as recurrent deep vein thrombosis (DVT) or recurrent pulmonary embolism (PE). The diagnosis of recurrent DVT was accepted if one of the following criteria was met: (a) a new, constant intraluminal‐filling defect not present on the last available venogram; (b) if the venogram was not diagnostic either an abnormal 125I‐fibrinogen leg scan or abnormal impedance plethysmogram or ultrasound result, which had been normal before the suspected recurrent episode (<a href="./references#CD001100-bbs2-0057" title="BullerHR , LensingAWA , HirshJ , tenCateJW . Deep venous thrombosis: new noninvasive tests. Thrombosis and Haemostasis1991;66(1):133‐9. ">Buller 1991</a>). The diagnosis of PE was accepted if one of the following criteria was met: (a) a segmental defect on the perfusion lung scan that was unmatched on the ventilation scan or chest roentgenogram; (b) positive pulmonary angiography; (c) PE at autopsy.<br/> <sup>2</sup> Downgraded as risk of bias serious due to high risk of attrition bias in 4 studies (<a href="./references#CD001100-bbs2-0006" title="FiessingerJN , FernandezML , GattererE , OhlssonCG . Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial. Haemostasis1994;24(Suppl 1):Abstract 44. FiessingerJN , Lopez‐FernandezM , GattererE , GranqvistS , KherA , OlssonCG , et al. Once‐daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1996;76(2):195‐9. ">Fiessinger 1996</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0022" title="NinetJ , BachetP , PrandoniP , RuolA , VigoM , BarretA , et al. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1991;65(3):251‐6. ">Ninet 1991</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>), high risk of reporting bias in 2 studies (<a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>) and high risk of other bias in 3 studies (<a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>).<br/> <sup>3</sup> Downgraded as risk of bias serious due to high risk of attrition bias in 1 study (<a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>), high risk of reporting bias in one study (<a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>), and high risk of other bias in 2 studies (<a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>).<br/> <sup>4</sup> Downgraded as risk of bias serious due to high risk of attrition bias in 2 studies (<a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>), high risk of reporting bias in 2 studies (<a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>), and high risk of other bias in 3 studies (<a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>)<br/> <sup>5</sup> The number of participants in each group with an improved venographic score, if pre‐ and post‐treatment venograms were obtained and were assessed by persons unaware of treatment assignment.<br/> <sup>6</sup> Downgraded as risk of bias serious due to high risk of selection bias in 1 study (<a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>), high risk of attrition bias in 6 studies (<a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>; <a href="./references#CD001100-bbs2-0006" title="FiessingerJN , FernandezML , GattererE , OhlssonCG . Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial. Haemostasis1994;24(Suppl 1):Abstract 44. FiessingerJN , Lopez‐FernandezM , GattererE , GranqvistS , KherA , OlssonCG , et al. Once‐daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1996;76(2):195‐9. ">Fiessinger 1996</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0022" title="NinetJ , BachetP , PrandoniP , RuolA , VigoM , BarretA , et al. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1991;65(3):251‐6. ">Ninet 1991</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>), high risk of reporting bias in 1 study (<a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>), and high risk of other bias in 4 studies (<a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>). Downgraded further due to moderate heterogeneity (I² = 56%)<br/> <sup>7</sup> Haemorrhages were classified as major if they were intracranial, retroperitoneal, led directly to death, necessitated transfusion or they led to the interruption of antithrombotic treatment or (re)operation.<br/> <sup>8</sup> Downgraded as risk of bias serious due to high risk of selection bias in 1 study (<a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>), high risk of attrition bias in 5 studies (<a href="./references#CD001100-bbs2-0006" title="FiessingerJN , FernandezML , GattererE , OhlssonCG . Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial. Haemostasis1994;24(Suppl 1):Abstract 44. FiessingerJN , Lopez‐FernandezM , GattererE , GranqvistS , KherA , OlssonCG , et al. Once‐daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1996;76(2):195‐9. ">Fiessinger 1996</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0022" title="NinetJ , BachetP , PrandoniP , RuolA , VigoM , BarretA , et al. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1991;65(3):251‐6. ">Ninet 1991</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>), high risk of reporting bias in 2 studies (<a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>), and high risk of other bias in 5 studies (<a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>).<br/> <sup>9</sup> Downgraded as risk of bias serious due to high risk of selection bias in 1 study (<a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>), high risk of attrition bias in 4 studies (<a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>), high risk of reporting bias in 2 studies (<a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>), and high risk of other bias in 5 studies (<a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001100-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001100-sec-0023"></div> <section id="CD001100-sec-0024"> <h3 class="title" id="CD001100-sec-0024">Description of the condition</h3> <p>Venous thromboembolism (presence of a blood clot in the veins, VTE) has an incidence in the general population of approximately 0.1% per year. Its main manifestations are leg complaints, due to deep venous thrombosis (DVT), in the lower limb (blood clot in the deep veins of the leg), and signs of dyspnoea (shortness of breath) and pleuritic thoracic pain (chest pain) when a thrombus (clot) becomes dislodged and forms an embolism obstructing blood flow in the pulmonary circulation. Evidence suggests that although people may only complain about either DVT or pulmonary embolism (PE), in many cases the pathological manifestations are shared between these two clinically distinct conditions (<a href="./references#CD001100-bbs2-0066" title="HuismanMV , BullerHR , tenCateJW , vanRoyenEA , VreekenJ , KerstenMJ , et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep vein thrombosis. Chest1989;95(3):498‐502. ">Huisman 1989</a>; <a href="./references#CD001100-bbs2-0067" title="HullRD , HirshJ , CarterCJ , JayRM , DoddPE , OckelfordPA , et al. Pulmonary angiography, ventilation lung scanning, and venography for suspected pulmonary embolism with abnormal perfusion lung scan. Annals of Internal Medicine1983;98(6):891‐9. ">Hull 1983</a>). Therefore, increasingly they are referred to as one disease and are treated with comparable anticoagulant regimens. </p> </section> <section id="CD001100-sec-0025"> <h3 class="title" id="CD001100-sec-0025">Description of the intervention</h3> <p>Anticoagulant therapy is the treatment of choice for most people with VTE (<a href="./references#CD001100-bbs2-0070" title="NICE . Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. www.nice.org.uk/guidance/cg144 (accessed 15 November 2016). ">NICE 2012</a>). Present guidelines recommend initial therapy for DVT with a parenteral anticoagulant (unfractionated heparin (UFH), low molecular weight heparin (LMWH) or fondaparinux) followed by vitamin K antagonist (VKA) therapy (<a href="./references#CD001100-bbs2-0068" title="KearonC , AklEA , ComerotaAJ , PrandoniP , BounameauxH , GoldhaberSZ , et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e419S‐94S. ">Kearon 2012</a>). Heparin is administered by either continuous intravenous (IV) infusion or twice daily subcutaneous injection (<a href="./references#CD001100-bbs2-0070" title="NICE . Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. www.nice.org.uk/guidance/cg144 (accessed 15 November 2016). ">NICE 2012</a>). Heparin dosage is monitored by the activated partial thromboplastin time (APTT) and adjusted to maintain the anticoagulant effect within a defined therapeutic range. For intravenous heparin therapy to achieve its minimal anticoagulant effect, the initial dosing needs to be either weight based (80 units/kg then 18 units/kg/hour) or a fixed dose using a 5000 unit bolus followed by at least 1250 units/hour (<a href="./references#CD001100-bbs2-0068" title="KearonC , AklEA , ComerotaAJ , PrandoniP , BounameauxH , GoldhaberSZ , et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e419S‐94S. ">Kearon 2012</a>). Laboratory monitoring is necessary because the anticoagulant response to heparin is highly variable among people with VTE. Inadequate heparin dosing is related to an increased risk of VTE recurrence (<a href="./references#CD001100-bbs2-0075" title="TurpieAGG , ChinBSP , LipGYH . Venous thromboembolism: treatment strategies. British Medical Journal2002;325(7370):948‐50. ">Turpie 2002</a>). </p> </section> <section id="CD001100-sec-0026"> <h3 class="title" id="CD001100-sec-0026">Why it is important to do this review</h3> <p>A number of LMWH preparations and heparinoids have been developed for clinical use. Compared with UFH, LMWH preparations have a longer plasma half‐life, less inter‐individual variability in anticoagulant response to fixed doses and, in animal models, a more favourable antithrombotic to haemorrhagic ratio (<a href="./references#CD001100-bbs2-0064" title="HirshJ . From unfractionated heparins to low molecular weight heparins. Acta Chirurgica Scandinavica1990;156 Suppl 556:42‐50. ">Hirsh 1990</a>; <a href="./references#CD001100-bbs2-0065" title="HirshJ , LevineMN . Low molecular weight heparin. Blood1992;79(1):1‐17. ">Hirsh 1992</a>). As a result of their pharmacokinetic properties, a stable and sustained anticoagulant effect is achieved when LMWHs are administered subcutaneously once or twice daily, without laboratory monitoring. Although most experience with LMWHs has been in the prevention of VTE, where they have been shown to be safe and effective (<a href="./references#CD001100-bbs2-0071" title="NurmohamedMT , RosendaalFR , BullerHR , DekkerE , HommesDW , VandenbrouckeJP , et al. Low‐molecular‐weight heparin versus standard heparin in general and orthopaedic surgery: a meta‐analysis. Lancet1992;340(8812):152‐6. ">Nurmohamed 1992</a>), there is accumulating evidence that these anticoagulants are also safe and effective for the initial treatment of venous thromboembolic events. This is the third update of the Cochrane Review first published in 1999. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001100-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001100-sec-0027"></div> <p>To evaluate the efficacy and safety of fixed dose subcutaneous low molecular weight heparin compared to adjusted dose unfractionated heparin (intravenous or subcutaneous) for the initial treatment of people with venous thromboembolism (acute deep venous thrombosis or pulmonary embolism). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001100-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001100-sec-0028"></div> <section id="CD001100-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001100-sec-0030"> <h4 class="title">Types of studies</h4> <p>Randomised controlled clinical trials (RCTs) with prospective follow‐up.</p> </section> <section id="CD001100-sec-0031"> <h4 class="title">Types of participants</h4> <p>People with venous thromboembolism (acute deep venous thrombosis or pulmonary embolism) confirmed by objective tests. </p> </section> <section id="CD001100-sec-0032"> <h4 class="title">Types of interventions</h4> <p>Initial treatment (usually in the first five to 14 days) with fixed dose subcutaneous low molecular weight heparin (LMWH) and adjusted dose unfractionated heparin (UFH) (intravenous or subcutaneous). </p> </section> <section id="CD001100-sec-0033"> <h4 class="title">Types of outcome measures</h4> <section id="CD001100-sec-0034"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD001100-list-0001"> <li> <p>Incidence of symptomatic recurrent venous thromboembolism (deep venous thrombosis or pulmonary embolism) during the initial treatment and during follow‐up. </p> </li> </ul> </p> </section> <section id="CD001100-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD001100-list-0002"> <li> <p>Number of participants in whom the thrombus size reduced based on pre‐ and post‐treatment venograms. </p> </li> </ul> <ul id="CD001100-list-0003"> <li> <p>Frequency of major haemorrhagic episodes during initial treatment or within 48 hours after treatment cessation. </p> </li> </ul> <ul id="CD001100-list-0004"> <li> <p>Overall mortality at the end of follow‐up.</p> </li> </ul> </p> </section> </section> </section> <section id="CD001100-sec-0036"> <h3 class="title">Search methods for identification of studies</h3> <p>There were no language restrictions.</p> <section id="CD001100-sec-0037"> <h4 class="title">Electronic searches</h4> <p>For this update the Cochrane Vascular Information Specialist (CIS) searched the following databases for relevant trials. </p> <p> <ul id="CD001100-list-0005"> <li> <p>The Cochrane Vascular Specialised Register (searched 15 September 2016).</p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 8) in the Cochrane Library (searched 15 September 2016). </p> </li> </ul> </p> <p>See <a href="./appendices#CD001100-sec-0088">Appendix 1</a> for details of the search strategy used to search CENTRAL. </p> <p>The Cochrane Vascular Specialised Register is maintained by the CIS and is constructed from weekly electronic searches of MEDLINE Ovid, Embase Ovid, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies, used are described in the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html" target="_blank">Specialised Register</a> section of the Cochrane Vascular module in the Cochrane Library (<a href="http://www.cochranelibrary.com/" target="_blank">www.cochranelibrary.com</a>). </p> <p>The CIS searched the following trial registries for details of ongoing and unpublished studies. </p> <p> <ul id="CD001100-list-0006"> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.ClinicalTrials.gov</a>). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/trialsearch</a>). </p> </li> <li> <p>ISRCTN Register (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>). </p> </li> </ul> </p> </section> <section id="CD001100-sec-0038"> <h4 class="title">Searching other resources</h4> <p>We also reviewed the reference lists of relevant papers identified from these searches.</p> </section> </section> <section id="CD001100-sec-0039"> <h3 class="title" id="CD001100-sec-0039">Data collection and analysis</h3> <section id="CD001100-sec-0040"> <h4 class="title">Selection of studies</h4> <p>For this 2016 update, two review authors (LR and LJ) independently assessed studies identified by the searches for eligibility. Any disagreements were resolved by discussion. </p> <p>Studies were excluded if:<br/> (1) they were dose‐ranging studies using higher doses of LMWH than are currently in use;<br/> (2) they used LMWH intravenously;<br/> (3) they adjusted LMWH dosages after initiation of treatment;<br/> (4) the difference in initial treatment was confounded by differences in concomitant medication or long‐term medication;<br/> (5) a true LMWH was not used (by true LMWH we mean that no compounds other than heparins were present);<br/> (6) the administration of UFH was suboptimal (i.e. not an adjusted dose);<br/> (7) the report was an abstract with incomplete data. </p> </section> <section id="CD001100-sec-0041"> <h4 class="title">Data extraction and management</h4> <p>Data were extracted by two review authors (LR and LJ) and included route of administration, intensity of heparin therapy, intensity of oral anticoagulant therapy and the performance of independent assessment of study outcomes. </p> <p>In addition, the following data were extracted.</p> <p>(1) The incidence of symptomatic recurrent DVT and PE during the initial treatment and during follow‐up (if active follow‐up was conducted prospectively at the study centres); whether this incidence was assessed by persons unaware of treatment assignment; and if valid criteria were used for the diagnosis of recurrent VTE. </p> <p>The diagnosis of recurrent DVT was accepted if one of the following criteria was met.<br/> (a) A new, constant intraluminal filling defect not present on the last available venogram.<br/> (b) If the venogram was not diagnostic, either an abnormal 125I‐fibrinogen leg scan or abnormal impedance plethysmogram or ultrasound result, which had been normal before the suspected recurrent episode (<a href="./references#CD001100-bbs2-0057" title="BullerHR , LensingAWA , HirshJ , tenCateJW . Deep venous thrombosis: new noninvasive tests. Thrombosis and Haemostasis1991;66(1):133‐9. ">Buller 1991</a>). </p> <p>The diagnosis of PE was accepted if one of the following criteria was met.<br/> (a) A segmental defect on the perfusion lung scan that was unmatched on the ventilation scan or chest roentgenogram.<br/> (b) Positive pulmonary angiography.<br/> (c) Pulmonary embolism at autopsy. </p> <p>(2) The number of participants in each group with an improved venographic score, if pre‐ and post‐treatment venograms were obtained and were assessed by persons unaware of treatment assignment. </p> <p>(3) The frequency of major haemorrhagic episodes during initial treatment. Haemorrhages were classified as major if they were intracranial, retroperitoneal, led directly to death, necessitated transfusion or they led to the interruption of antithrombotic treatment or (re)operation. All other haemorrhages were classified as minor. </p> <p>(4) The overall mortality at the end of follow‐up, specified for participants with or without malignant disease, if active follow‐up was prospectively conducted at the study centres. </p> </section> <section id="CD001100-sec-0042"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The risk of bias for all newly included studies was assessed by two review authors (LR and LJ) according to the guidelines given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001100-bbs2-0062" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). The following domains were assessed as being at either a low risk of bias, high risk of bias or unclear risk of bias using the criteria as described in Chapter 8.5 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001100-bbs2-0063" title="HigginsJPT , AltmanDG , SterneJAC , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). </p> <p> <ol id="CD001100-list-0007"> <li> <p>Sequence generation: was the allocation sequence adequately generated?</p> </li> <li> <p>Allocation treatment: was allocation adequately concealed?</p> </li> <li> <p>Blinding: was knowledge of the allocated interventions adequately prevented during the study? </p> </li> <li> <p>Incomplete data: were incomplete outcome data adequately addressed?</p> </li> <li> <p>Selective outcome reporting: were reports of the study free of suggestion of selective outcome reporting? </p> </li> <li> <p>Other potential threats to validity: was the study apparently free of other factors that could put it at risk of bias? </p> </li> </ol> </p> <p>We resolved disagreements by discussion and consensus.</p> </section> <section id="CD001100-sec-0043"> <h4 class="title">Measures of treatment effect</h4> <p>We based reduction in thrombus size on the number of participants whose thrombus size reduced between pre‐ and post‐treatment venograms. We used this outcome and each of the other dichotomous outcomes for the different treatments to calculate an odds ratio (OR) with 95% confidence intervals (CI) separately for each trial. We then combined these ORs across studies, giving due weight to the number of events in each of the two treatment groups in each separate study using the Peto procedure, which assumes a fixed treatment effect (<a href="./references#CD001100-bbs2-0058" title="CollinsR , GrayR , GodwinJ , PetoR . Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Statistics in Medicine1987;6(3):245‐50. ">Collins 1987</a>; <a href="./references#CD001100-bbs2-0069" title="MantelN , HaenszelW . Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute1959;22(4):719‐48. ">Mantel 1959</a>). We investigated pulmonary vascular obstruction by calculating the mean difference (MD) between the groups. </p> <p>We performed all these analyses with the individual LMWH preparations for VTE (that is DVT and PE combined). </p> <p>We performed an analysis for all LMWH preparations combined if the treatment effects of the individual LMWH preparations were compatible with each other, in view of the biochemical heterogeneity as well as the heterogeneity in animal experiments. </p> <p>We addressed the validity of combining the trials with a statistical test of homogeneity, which considers whether differences in treatment effect over the individual trials are consistent with natural variation around a constant effect (<a href="./references#CD001100-bbs2-0058" title="CollinsR , GrayR , GodwinJ , PetoR . Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Statistics in Medicine1987;6(3):245‐50. ">Collins 1987</a>). </p> </section> <section id="CD001100-sec-0044"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis in this review was the individual participant.</p> </section> <section id="CD001100-sec-0045"> <h4 class="title">Dealing with missing data</h4> <p>We sought information about drop‐outs, withdrawals and other missing data and, if not reported, we contacted study authors for this information but did not get a response. </p> </section> <section id="CD001100-sec-0046"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between the trials by visual examination of the forest plot to check for overlapping CIs, the Chi² test for homogeneity with a 10% level of significance and we used the I² statistic to measure the degree of inconsistency between the studies. An I² result of greater than 50% may represent moderate to substantial heterogeneity (<a href="./references#CD001100-bbs2-0059" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> </section> <section id="CD001100-sec-0047"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed publication bias by funnel plots if a sufficient number of studies (10 or more) were available in the meta‐analyses. There are many reasons for funnel plot asymmetry, and we consulted the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to aid the interpretation of the results (<a href="./references#CD001100-bbs2-0074" title="SterneJAC , EggerM , MoherD . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). </p> </section> <section id="CD001100-sec-0048"> <h4 class="title">Data synthesis</h4> <p>One review author (LR) entered the data into Review Manager 5 (<a href="./references#CD001100-bbs2-0072" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), and the second review author (LJ) cross‐checked data entry. We resolved any discrepancies by consulting the source publication. We used a fixed‐effect model to meta‐analyse the data. </p> </section> <section id="CD001100-sec-0049"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed subgroup analysis for the different heparin drugs versus unfractionated heparin for all the primary and secondary outcomes of the review. </p> <p>We also performed the following additional analyses by different groups of interest.</p> <p> <ul id="CD001100-list-0008"> <li> <p>Proximal deep vein thrombosis.</p> </li> <li> <p>Pulmonary embolism.</p> </li> <li> <p>Venous thromboembolism with or without malignant disease.</p> </li> <li> <p>Subcutaneous UFH versus LMWH.</p> </li> <li> <p>Intravenous UFH versus LMWH.</p> </li> </ul> </p> <p>For these additional analyses, for the outcome 'recurrent VTE' we report the time point 'end of follow‐up' data only. </p> <p>We also performed a separate analysis to explore any trend over time.</p> </section> <section id="CD001100-sec-0050"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses by excluding studies with inadequate concealment of allocation prior to randomisation. </p> <p>We also performed a sensitivity analysis by excluding studies that did not use the following International Society on Thrombosis and Haemostasis (ISTH) criteria of major bleeding (<a href="./references#CD001100-bbs2-0073" title="SchulmanS , KearonC , and the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients. Journal of Thrombosis and Haemostasis2005;3(4):692‐4. ">Schulman 2005</a>). </p> <p> <ul id="CD001100-list-0009"> <li> <p>Fatal bleeding.</p> </li> <li> <p>Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra‐articular or pericardial, or intramuscular with compartment syndrome. </p> </li> <li> <p>Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells. </p> </li> <li> <p>Any combination of the above.</p> </li> </ul> </p> <section id="CD001100-sec-0051"> <h5 class="title">Summary of findings</h5> <p>We created 'Summary of findings' tables for LMWH compared with UFH in participants with VTE (<a href="./full#CD001100-tbl-0001">summary of findings Table for the main comparison</a>). We used GRADEpro GDT software and the GRADE approach to assess the quality of the evidence for the most clinically relevant outcomes as described in <a href="#CD001100-sec-0033">Types of outcome measures</a>. We downgraded the evidence from 'high quality' for serious or very serious study limitations (risk of bias, indirectness and inconsistency of evidence, imprecision of effect estimates or potential publication bias) according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001100-bbs2-0062" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>) and the GRADE Working Group (<a href="./references#CD001100-bbs2-0061" title="GuyattGH , OxmanAD , VistGE , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. British Medical Journal2008;336(7650):924‐6. ">GRADE Working Group 2008</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001100-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001100-sec-0052"></div> <section id="CD001100-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD001100-sec-0054"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD001100-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD001100-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001100-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD001100-sec-0055"> <h4 class="title">Included studies</h4> <p>Six additional studies were included in this update (<a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0014" title="LeizoroviczA . Tinzaparin compared to unfractionated heparin for initial treatment of deep vein thrombosis in very elderly patients with renal insufficiency ‐ the IRIS trial. Blood2008; Vol. 112, issue 11:434. LeizoroviczA , SiguretV , MottierD . Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep((R)) in Renal Insufficiency Study (IRIS). Thrombosis Research2011;128(1):27‐34. NCT00277394 . Innohep© in elderly patients with impaired renal function treated for acute deep vein thrombosis. clinicaltrials.gov/ct/show/NCT002773942007. SiguretV , DeudonC , GolmardJ , LeizoroviczA , PautasE , Gouin‐ThibaultI . Pharmacodynamic response to unfractionated heparin used for initial treatment of acute deep vein thrombosis in elderly patients with renal impairment. A substudy of the IRIS clinical trial. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):805. ">Leizorovicz 2011</a>; <a href="./references#CD001100-bbs2-0020" title="MeyerG , BrenotF , PacouretG , SimonneauG , Gillet JuvinK , CharbonnierB , et al. Subcutaneous low‐molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thrombosis and Haemostasis1995;74(6):1432‐5. ">Meyer 1995</a>; <a href="./references#CD001100-bbs2-0021" title="Moreno‐PalomaresJJ , Fisac‐HerreroRM , Herrero DomingoA , Ferreira‐PasosEM , GrasaJ , Reverte CejudoD . [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis]. Anales de Medicina Interna2001;18(7):364‐8. ">Moreno‐Palomares 2001</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>). In total, 29 studies were truly randomised trials, published between 1988 and the end of 2011, with a total of 10,390 participants. Fourteen of the 29 studies included participants with symptomatic deep venous thrombosis of the leg without symptoms of pulmonary embolism. In eight of these 14 studies people with distal deep venous thrombosis were included as well as people with proximal deep venous thrombosis. In nine studies participants were included if they had symptomatic deep venous thrombosis of the leg, with or without symptomatic pulmonary embolism; or asymptomatic deep venous thrombosis of the leg with symptomatic pulmonary embolism; or symptomatic deep venous thrombosis or pulmonary embolism. In four studies participants with pulmonary embolism only were included. All studies used objective diagnostic tests to confirm the diagnosis. </p> <p>All of the included studies considered fixed dose subcutaneous LMWH once daily (<a href="./references#CD001100-bbs2-0006" title="FiessingerJN , FernandezML , GattererE , OhlssonCG . Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial. Haemostasis1994;24(Suppl 1):Abstract 44. FiessingerJN , Lopez‐FernandezM , GattererE , GranqvistS , KherA , OlssonCG , et al. Once‐daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1996;76(2):195‐9. ">Fiessinger 1996</a>; <a href="./references#CD001100-bbs2-0010" title="HullRD , RaskobGE , BrantRF , PineoGF , ElliottG , SteinPD , et al. Low‐molecular‐weight heparin vs heparin in the treatment of patients with pulmonary embolism. American‐Canadian Thrombosis Study Group. Archives of Internal Medicine2000;160(2):229‐36. HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low‐molecular‐weight heparin compared with continuous intravenous heparin in the treatment of proximal‐vein thrombosis. New England Journal of Medicine1992;326(15):975‐82. ">Hull 1992</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0014" title="LeizoroviczA . Tinzaparin compared to unfractionated heparin for initial treatment of deep vein thrombosis in very elderly patients with renal insufficiency ‐ the IRIS trial. Blood2008; Vol. 112, issue 11:434. LeizoroviczA , SiguretV , MottierD . Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep((R)) in Renal Insufficiency Study (IRIS). Thrombosis Research2011;128(1):27‐34. NCT00277394 . Innohep© in elderly patients with impaired renal function treated for acute deep vein thrombosis. clinicaltrials.gov/ct/show/NCT002773942007. SiguretV , DeudonC , GolmardJ , LeizoroviczA , PautasE , Gouin‐ThibaultI . Pharmacodynamic response to unfractionated heparin used for initial treatment of acute deep vein thrombosis in elderly patients with renal impairment. A substudy of the IRIS clinical trial. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):805. ">Leizorovicz 2011</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>; <a href="./references#CD001100-bbs2-0028" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJ‐P , AzarianR , et al. for the THESEE Study Group. A comparison of low‐molecular‐weight heparin with unfractionated heparin for acute pulmonary embolism. New England Journal of Medicine1997;337(10):663‐9. ">Simonneau 1997</a>), twice daily (<a href="./references#CD001100-bbs2-0001" title="BelcaroG , NicolaidesAN , CesaroneMR , LauroraG , DeSanctisMT , IncandelaL , et al. Comparison of low‐molecular‐weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep‐vein thrombosis. Angiology1999;50(10):781‐7. ">Belcaro 1999</a>; <a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>; <a href="./references#CD001100-bbs2-0003" title="DouketisJD , FosterGA , CrowtherMA , PrinsMH , GinsbergJS . Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine2000;160(22):3431‐6. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep‐vein thrombosis and pulmonary embolism. Blood1996; Vol. 88:626a. The Columbus Investigators. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657‐62. tenCateJW , BüllerHR , GentM , GallusAS , GinsbergJ , PrinsMH , et al. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. Journal of Vascular and Interventional Radiology1998;9:178. ">Columbus 1997</a>; <a href="./references#CD001100-bbs2-0004" title="DecoususH , LeizoroviczA , ParentF , PageY , TardyB , GirardPH , et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep‐vein thrombosis. New England Journal of Medicine1998;338(7):409‐15. ">Decousus 1998</a>; <a href="./references#CD001100-bbs2-0005" title="FaivreR , NeuhartE , KiefferY , ToulemondeF , BassandJP , MauratJP . Subcutaneous administration of a low molecular weight heparin (CY 222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis. Thrombosis and Haemostasis1987;58(1):Abstract 430. FaivreR , NeuhartY , KiefferY , ApfelF , MagninD , DidierD , et al. A new treatment of deep vein thrombosis: low molecular weight heparin fractions. Randomised study [Un nouveau traitement des thromboses veineuses profondes: les fractions d'heparine de bas poids moleculaire. Etude randomisee]. Presse Medicale1988;17(5):197‐200. ">Faivre 1988</a>; <a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0008" title="GoldhaberSZ , MorrisonRB , DiranLL , CreagerMA , LeeTHJr . Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Archives of Internal Medicine1998;158(21):2325‐8. ">Goldhaber 1998</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0012" title="KirchmaierCM , WolfH , SchaferH , EhlersB , BreddinHK . Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin‐Study Group. International Angiology1998;17(3):135‐45. ">Kirchmaier 1998</a>; <a href="./references#CD001100-bbs2-0013" title="KoopmanMMW , PrandoniP , PiovellaF , OckelfordPA , BrandjesDPM , van denMeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low‐molecular‐weight heparin administered at home. New England Journal of Medicine1996;334(11):682‐7. ">Koopman 1996</a>; <a href="./references#CD001100-bbs2-0015" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low‐molecular‐weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep‐vein thrombosis. New England Journal of Medicine1996;334(11):677‐81. ">Levine 1996</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0020" title="MeyerG , BrenotF , PacouretG , SimonneauG , Gillet JuvinK , CharbonnierB , et al. Subcutaneous low‐molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thrombosis and Haemostasis1995;74(6):1432‐5. ">Meyer 1995</a>; <a href="./references#CD001100-bbs2-0022" title="NinetJ , BachetP , PrandoniP , RuolA , VigoM , BarretA , et al. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1991;65(3):251‐6. ">Ninet 1991</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>; <a href="./references#CD001100-bbs2-0025" title="PrandoniP , CarnovaliM , MarchioriA . Subcutaneous adjusted‐dose unfractionated heparin vs fixed‐dose low‐molecular‐weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164:1077‐83. ">Prandoni 2004</a>; <a href="./references#CD001100-bbs2-0026" title="RiessH , KoppenhagenK , TolleA , Kemkes‐MatthesB , GraveM , PatekF , et al. Fixed‐dose, body weight‐independent subcutaneous low molecular weight heparin Certoparin compared with adjusted‐dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thrombosis and Haemostasis2003;90(2):252‐9. RiessH , KoppenhagenK , TolleAR , Kemkes‐MatthesB , GraveM , HarenbergJ , et al. Fixed‐dose body weight‐independent subcutaneous LMW‐heparin (LMWH) certoparin is equally effective to adjusted‐dose intravenous uf‐heparin (UFH) for the initial treatment of proximal deep venous thrombosis (DVT). Annals of Hematology2001;80 Suppl 1:A56. ">Riess 2003</a>; <a href="./references#CD001100-bbs2-0027" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis. Archives of Internal Medicine1993;153(13):1541‐6. ">Simonneau 1993</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>), or both (<a href="./references#CD001100-bbs2-0019" title="MerliG , SpiroTE , OlssonCG , AbildgaardU , DavidsonBL , EldorA , et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191‐202. SpiroTE , The Enoxaparin Clinical Trial Group. A multicenter clinical trial comparing once and twice‐daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1997;374(Suppl):Abstract SC 1527. deLissovoyG , YusenRD , SpiroTE , KrupskiWC , ChampionAH , SorensenSV . Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Archives of Internal Medicine2000;160(20):3160‐5. ">Merli 2001</a>; <a href="./references#CD001100-bbs2-0021" title="Moreno‐PalomaresJJ , Fisac‐HerreroRM , Herrero DomingoA , Ferreira‐PasosEM , GrasaJ , Reverte CejudoD . [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis]. Anales de Medicina Interna2001;18(7):364‐8. ">Moreno‐Palomares 2001</a>) compared with adjusted intravenous dose UFH (<a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>; <a href="./references#CD001100-bbs2-0003" title="DouketisJD , FosterGA , CrowtherMA , PrinsMH , GinsbergJS . Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine2000;160(22):3431‐6. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep‐vein thrombosis and pulmonary embolism. Blood1996; Vol. 88:626a. The Columbus Investigators. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657‐62. tenCateJW , BüllerHR , GentM , GallusAS , GinsbergJ , PrinsMH , et al. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. Journal of Vascular and Interventional Radiology1998;9:178. ">Columbus 1997</a>; <a href="./references#CD001100-bbs2-0004" title="DecoususH , LeizoroviczA , ParentF , PageY , TardyB , GirardPH , et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep‐vein thrombosis. New England Journal of Medicine1998;338(7):409‐15. ">Decousus 1998</a>; <a href="./references#CD001100-bbs2-0006" title="FiessingerJN , FernandezML , GattererE , OhlssonCG . Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial. Haemostasis1994;24(Suppl 1):Abstract 44. FiessingerJN , Lopez‐FernandezM , GattererE , GranqvistS , KherA , OlssonCG , et al. Once‐daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1996;76(2):195‐9. ">Fiessinger 1996</a>; <a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0008" title="GoldhaberSZ , MorrisonRB , DiranLL , CreagerMA , LeeTHJr . Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Archives of Internal Medicine1998;158(21):2325‐8. ">Goldhaber 1998</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0010" title="HullRD , RaskobGE , BrantRF , PineoGF , ElliottG , SteinPD , et al. Low‐molecular‐weight heparin vs heparin in the treatment of patients with pulmonary embolism. American‐Canadian Thrombosis Study Group. Archives of Internal Medicine2000;160(2):229‐36. HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low‐molecular‐weight heparin compared with continuous intravenous heparin in the treatment of proximal‐vein thrombosis. New England Journal of Medicine1992;326(15):975‐82. ">Hull 1992</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0012" title="KirchmaierCM , WolfH , SchaferH , EhlersB , BreddinHK . Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin‐Study Group. International Angiology1998;17(3):135‐45. ">Kirchmaier 1998</a>; <a href="./references#CD001100-bbs2-0013" title="KoopmanMMW , PrandoniP , PiovellaF , OckelfordPA , BrandjesDPM , van denMeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low‐molecular‐weight heparin administered at home. New England Journal of Medicine1996;334(11):682‐7. ">Koopman 1996</a>; <a href="./references#CD001100-bbs2-0015" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low‐molecular‐weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep‐vein thrombosis. New England Journal of Medicine1996;334(11):677‐81. ">Levine 1996</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>; <a href="./references#CD001100-bbs2-0019" title="MerliG , SpiroTE , OlssonCG , AbildgaardU , DavidsonBL , EldorA , et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191‐202. SpiroTE , The Enoxaparin Clinical Trial Group. A multicenter clinical trial comparing once and twice‐daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1997;374(Suppl):Abstract SC 1527. deLissovoyG , YusenRD , SpiroTE , KrupskiWC , ChampionAH , SorensenSV . Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Archives of Internal Medicine2000;160(20):3160‐5. ">Merli 2001</a>; <a href="./references#CD001100-bbs2-0020" title="MeyerG , BrenotF , PacouretG , SimonneauG , Gillet JuvinK , CharbonnierB , et al. Subcutaneous low‐molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thrombosis and Haemostasis1995;74(6):1432‐5. ">Meyer 1995</a>; <a href="./references#CD001100-bbs2-0021" title="Moreno‐PalomaresJJ , Fisac‐HerreroRM , Herrero DomingoA , Ferreira‐PasosEM , GrasaJ , Reverte CejudoD . [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis]. Anales de Medicina Interna2001;18(7):364‐8. ">Moreno‐Palomares 2001</a>; <a href="./references#CD001100-bbs2-0022" title="NinetJ , BachetP , PrandoniP , RuolA , VigoM , BarretA , et al. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1991;65(3):251‐6. ">Ninet 1991</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>; <a href="./references#CD001100-bbs2-0027" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis. Archives of Internal Medicine1993;153(13):1541‐6. ">Simonneau 1993</a>; <a href="./references#CD001100-bbs2-0028" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJ‐P , AzarianR , et al. for the THESEE Study Group. A comparison of low‐molecular‐weight heparin with unfractionated heparin for acute pulmonary embolism. New England Journal of Medicine1997;337(10):663‐9. ">Simonneau 1997</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>) or subcutaneous unfractionated heparin (<a href="./references#CD001100-bbs2-0005" title="FaivreR , NeuhartE , KiefferY , ToulemondeF , BassandJP , MauratJP . Subcutaneous administration of a low molecular weight heparin (CY 222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis. Thrombosis and Haemostasis1987;58(1):Abstract 430. FaivreR , NeuhartY , KiefferY , ApfelF , MagninD , DidierD , et al. A new treatment of deep vein thrombosis: low molecular weight heparin fractions. Randomised study [Un nouveau traitement des thromboses veineuses profondes: les fractions d'heparine de bas poids moleculaire. Etude randomisee]. Presse Medicale1988;17(5):197‐200. ">Faivre 1988</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0025" title="PrandoniP , CarnovaliM , MarchioriA . Subcutaneous adjusted‐dose unfractionated heparin vs fixed‐dose low‐molecular‐weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164:1077‐83. ">Prandoni 2004</a>) or both (<a href="./references#CD001100-bbs2-0001" title="BelcaroG , NicolaidesAN , CesaroneMR , LauroraG , DeSanctisMT , IncandelaL , et al. Comparison of low‐molecular‐weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep‐vein thrombosis. Angiology1999;50(10):781‐7. ">Belcaro 1999</a>; <a href="./references#CD001100-bbs2-0014" title="LeizoroviczA . Tinzaparin compared to unfractionated heparin for initial treatment of deep vein thrombosis in very elderly patients with renal insufficiency ‐ the IRIS trial. Blood2008; Vol. 112, issue 11:434. LeizoroviczA , SiguretV , MottierD . Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep((R)) in Renal Insufficiency Study (IRIS). Thrombosis Research2011;128(1):27‐34. NCT00277394 . Innohep© in elderly patients with impaired renal function treated for acute deep vein thrombosis. clinicaltrials.gov/ct/show/NCT002773942007. SiguretV , DeudonC , GolmardJ , LeizoroviczA , PautasE , Gouin‐ThibaultI . Pharmacodynamic response to unfractionated heparin used for initial treatment of acute deep vein thrombosis in elderly patients with renal impairment. A substudy of the IRIS clinical trial. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):805. ">Leizorovicz 2011</a>). Nine different preparations of LMWH were identified (nadroparin, tinzaparin, enoxaparin, dalteparin, CY 222, certoparin, ardeparin, reviparin and bemiparin). Ten trials did not have any post‐randomisation exclusions or losses to follow‐up. Eleven trials reported the number of participants lost to follow‐up, which ranged from 1.0% to 12.7%. One trial did not report the dropouts (see <a href="./references#CD001100-sec-0102" title="">Characteristics of included studies</a>). </p> </section> <section id="CD001100-sec-0056"> <h4 class="title">Excluded studies</h4> <p>Five additional studies were excluded for this update (<a href="./references#CD001100-bbs2-0048" title="QuirosM . Use of heparin of low molecular weight in the ambulatory handling of patients with deep venous thrombosis. Comparative study: heparin nondivided versus low molecular weight heparin. Revista costarricense de cardiologia2001;3(2):8‐13. ">Quiros 2001</a>; <a href="./references#CD001100-bbs2-0049" title="RiessH , BeckerLK , MelzerN , HarenbergJ . Treatment of deep vein thrombosis in patients with pulmonary embolism: Subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin. Blood Coagulation &amp; Fibrinolysis2014;25(8):838‐44. ">Riess 2014</a>; <a href="./references#CD001100-bbs2-0050" title="SiguretV , Gouin‐ThibaultI , PautasE , LeizoroviczA . No accumulation of the peak anti‐Xa activity of tinzaparin in elderly patients with moderate‐to‐severe renal impairment: the IRIS substudy. Journal of Thrombosis and Haemostasis2011;9(10):1966‐72. ">Siguret 2011</a>; <a href="./references#CD001100-bbs2-0051" title="StrickerH , MarchettiO , HaeberliA , MombelliG . Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis. Thrombosis and Haemostasis1999;82(4):1227‐31. ">Stricker 1999</a>; <a href="./references#CD001100-bbs2-0053" title="UcarEY , AkgunM , ArazO , TasH , KergetB , MeralM , et al. Comparison of LMWH versus UFH for hemorrhage and hospital mortality in the treatment of acute massive pulmonary thromboembolism after thrombolytic treatment: randomized controlled parallel group study. Lung. Springer New York LLC, 2015; Vol. 193, issue 1:121‐7. ">Ucar 2015</a>). A total of 26 trials were excluded for the following reasons: dosage of UFH was not adjusted (four trials: <a href="./references#CD001100-bbs2-0041" title="KearonC , GinsbergJJ , JulianJ , DouketisJ , SolymossS , OckelfordP , et al. Fixed‐dose, weight‐adjusted, unfractionated heparin (UFH) given subcutaneously (sc) without laboratory monitoring for acute treatment of venous thromboembolism (VTE): Randomized comparison with low‐molecular‐weight‐heparin (LMWH). Blood2004; Vol. 104, issue 11:Abstract 707. KearonC , GinsbergJS , JulianJ , DouketisJ , SolymossS , OckelfordP , et al. Acute treatment of venous thromboembolism (VTE) with fixed‐dose, weight‐adjusted, unfractionated heparin (UFH) given subcutaneously (sc) without laboratory monitoring: randomized comparison with low‐molecular‐weight‐heparin (LMWH). Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: OR147. KearonC , GinsbergJS , JulianJA , DouketisJ , SolymossS , OckelfordP , et al. Comparison of fixed‐dose weight‐adjusted‐unfractionated heparin and low‐molecular weight heparin for acute treatment of venous thromboembolism. JAMA2006;296:935‐42. ">Kearon 2006</a>; <a href="./references#CD001100-bbs2-0047" title="NotarbartoloA , SalanitriG , DaviG , AvernaM , BarbagalloC , CatalanoI . Low molecular weight heparin in the short and long‐term treatment of deep vein thrombosis in diabetic subjects. Praxis Med1988;9:393‐405. ">Notarbartolo 1988</a>; <a href="./references#CD001100-bbs2-0052" title="TedoldiA , BotticellaF , MalobertiMR . Antithrombophilic effect of low molecular weight heparins in patients with deep vein thrombosis. Clinical Trials and Meta‐analysis1993;28(4‐5):215‐25. ">Tedoldi 1993</a>; <a href="./references#CD001100-bbs2-0055" title="ZanghiM , MoriciV , CostanzoM , AstutoL , SalanitriG . Deep vein thrombosis of the legs: new therapy by means of low molecular weight heparins. Journal of International Medical Research1988;16(6):474‐84. ">Zanghi 1988</a>); dose‐ranging study (three trials: <a href="./references#CD001100-bbs2-0032" title="BangaJD , deValkHW , WesterJWJ , BrouwerCB , vanHessenMWJ , MeuwissenOJAT , et al. A dose finding study of subcutaneous heparinoid Oragaran (ORG 10172) twice daily compared to continuous intravenous unfractionated heparin in the treatment of venous thromboembolism. Thrombosis and Haemostasis1993;69:545 Abstract 20. ">Banga 1993</a>; <a href="./references#CD001100-bbs2-0035" title="deValkHW , BangaJD , WesterJWJ , BrouwerCB , vanHessenMWJ , MeuwissenOJAT , et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomised controlled trial. Annals of Internal Medicine1995;123(1):1‐9. ">de Valk 1995</a>; <a href="./references#CD001100-bbs2-0036" title="HandelandGF , AbildgaardU , HolmHA , ArnesenKE . Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. European Journal of Clinical Pharmacology1990;39(2):107‐12. ">Handeland 1990</a>); LMWH dosage was adjusted (four trials: <a href="./references#CD001100-bbs2-0030" title="AiachM , FiessingerJN , VitouxJF , LeQuerrecA , Gouault‐HeilmannM , et al. Deep vein thrombosis treatment. A comparative study: subcutaneous Fragmin versus unfractionated heparin administered by continuous infusion. Multicentre trial. [Traitement des thromboses veineuses profondes constituees. Etude comparative d'un fragment d'heparine de bas poids moleculaire (Fragmine) administree par voie sous‐cutanee et de l'heparine standard administree par voie intraveineuse continue. Etude multicentrique. [French]]. Revue de Medecine Interne1989;10(4):375‐81. ">Aiach 1989</a>; <a href="./references#CD001100-bbs2-0034" title="BrattG , AbergW , JohanssonM , TornebohmE , GranqvistS , LocknerD . Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1990;64(4):506‐10. ">Bratt 1990</a>; <a href="./references#CD001100-bbs2-0040" title="HolmHA , LyB , HandelandGF , AbildegaardU , ArnesenKE , GottschalkP , et al. Subcutaneous heparin treatment of deep vein thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis1986;16 Suppl 2:30‐7. ">Holm 1986</a>; <a href="./references#CD001100-bbs2-0044" title="LyB , ArnesenKE , HolmHA , HandelandGF , AbilgaardU . Subcutaneous LMW or unfractionated heparin in DVT: A randomized, double blind study with dose adjustments according to heparin concentration in plasma. Thrombosis and Haemostasis1985;54(1):Abstract No. 91. ">Ly 1985</a>); intravenous administration of LMWH (four trials: <a href="./references#CD001100-bbs2-0033" title="BrattG , TornebohmE , GranqvistS , AbergW , LocknerD . A comparison between low molecular weight heparin Kabi 2165 and standard heparin in the intravenous treatment of deep vein thrombosis. Thrombosis and Haemostasis1985;54(4):813‐7. ">Bratt 1985</a>; <a href="./references#CD001100-bbs2-0042" title="LocknerD , BrattG , TornebohmE , AbergW , GranqvistS . A comparison between low molecular weight heparin (LMWH, KABI 2165) and standard heparin in the intravenous treatment of deep vein thrombosis (DVT). Thrombosis and Haemostasis1985;54(4):813‐7. ">Lockner 1985</a>; <a href="./references#CD001100-bbs2-0043" title="LocknerD , BrattG , TornebohmE , AbergW , GranqvistS . Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis. Haemostasis1986;16 Suppl 2:25‐9. ">Lockner 1986</a>; <a href="./references#CD001100-bbs2-0054" title="VogelG , MachulikM . Efficacy and safety of a low molecular weight heparin (LMW‐heparin Sandoz) in patients with deep vein thrombosis. Thrombosis and Haemostasis1987;58 Suppl:Abstract No. 427. ">Vogel 1987</a>); results from participants treated for venous thrombosis of the upper limb and for pulmonary embolism could not be distinguished from those of participants with leg vein thrombosis and the outcome was incompletely evaluated (four trials: <a href="./references#CD001100-bbs2-0031" title="AlbadaJ , NieuwenhuisHK , SixmaJJ . Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Circulation1989;80(4):935‐40. ">Albada 1989</a>; <a href="./references#CD001100-bbs2-0037" title="HarenbergJ , HuckK , StehleG , MallK , SchwarzA , HeeneDL . Prospective randomized, controlled study on the treatment of deep venous thrombosis using low molecular weight heparin compared with unfractionated heparin. Thrombosis and Haemostasis1989;62:356 Abstract No. 1106. HarenbergJ , HuismanMV , TolleAR , BreddinHK , KirchmaierCM . Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed‐dose body weight‐independent low molecular weight heparin certoparin. Seminars in Thrombosis and Hemostasis2001;27:513‐8. HarenbergJ , RiessH , FischerH , BromJ , EidingerGW . Initial treatment of patients with acute deep‐vein thrombosis using 8.000 IU bid low‐molecular‐weight heparin certoparin ‐ A 24 months follow up. Journal of Thrombosis and Haemostasis2005;3(1):Abstract No. P1021. ">Harenberg 1989</a>; <a href="./references#CD001100-bbs2-0038" title="HarenbergJ , HuckK , BratschH , StehleG , DempfleCE , MallK , et al. Therapeutic application of subcutaneous low‐molecular‐weight heparin in acute venous thrombosis. Haemostasis1990;20 Suppl 1:205‐19. HarenbergJ , StehleG , BlauthM , HuckK , MallK , HeeneDL . Dosage, anticoagulant and antithrombotic effects of heparin and low‐molecular‐weight heparin in the treatment of deep vein thrombosis. Seminars in Thrombosis and Hemostasis1997;23(1):83‐90. ">Harenberg 1990</a>; <a href="./references#CD001100-bbs2-0039" title="HarenbergJ , BreddinHK , KirchmaierCM , TolleA . Does fixed dose body weight independent subcutaneous low‐molecular‐weight heparin improve the Marder score compared to adjusted dose unfractionated heparin in the treatment of venous thrombosis. Annals of Hematology2000;79 Suppl 1:A84. ">Harenberg 2000b</a>); a difference in long‐term treatment between the two treatment regimens (two trials: <a href="./references#CD001100-bbs2-0045" title="MonrealM , LafozE , VediaC , RoncalesJ . Comparison of subcutaneous unfractioned heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thrombosis and Haemostasis1993;69(649):Abstract No. 383. ">Monreal 1993</a>; <a href="./references#CD001100-bbs2-0046" title="MonrealM , LafozE , OliveA , deRioL . Comparison of subcutaneous unfractioned heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thrombosis and Haemostasis1994;71(1):7‐11. ">Monreal 1994</a>); no UFH comparison group (<a href="./references#CD001100-bbs2-0050" title="SiguretV , Gouin‐ThibaultI , PautasE , LeizoroviczA . No accumulation of the peak anti‐Xa activity of tinzaparin in elderly patients with moderate‐to‐severe renal impairment: the IRIS substudy. Journal of Thrombosis and Haemostasis2011;9(10):1966‐72. ">Siguret 2011</a>); one study looked at the effect of heparin on haemostatic markers and therefore the outcomes were not relevant for this review (<a href="./references#CD001100-bbs2-0051" title="StrickerH , MarchettiO , HaeberliA , MombelliG . Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis. Thrombosis and Haemostasis1999;82(4):1227‐31. ">Stricker 1999</a>); a substudy of a study already included in the original review (<a href="./references#CD001100-bbs2-0026" title="RiessH , KoppenhagenK , TolleA , Kemkes‐MatthesB , GraveM , PatekF , et al. Fixed‐dose, body weight‐independent subcutaneous low molecular weight heparin Certoparin compared with adjusted‐dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thrombosis and Haemostasis2003;90(2):252‐9. RiessH , KoppenhagenK , TolleAR , Kemkes‐MatthesB , GraveM , HarenbergJ , et al. Fixed‐dose body weight‐independent subcutaneous LMW‐heparin (LMWH) certoparin is equally effective to adjusted‐dose intravenous uf‐heparin (UFH) for the initial treatment of proximal deep venous thrombosis (DVT). Annals of Hematology2001;80 Suppl 1:A56. ">Riess 2003</a>); not an RCT (<a href="./references#CD001100-bbs2-0048" title="QuirosM . Use of heparin of low molecular weight in the ambulatory handling of patients with deep venous thrombosis. Comparative study: heparin nondivided versus low molecular weight heparin. Revista costarricense de cardiologia2001;3(2):8‐13. ">Quiros 2001</a>); and treatment with thrombolytic therapy (<a href="./references#CD001100-bbs2-0053" title="UcarEY , AkgunM , ArazO , TasH , KergetB , MeralM , et al. Comparison of LMWH versus UFH for hemorrhage and hospital mortality in the treatment of acute massive pulmonary thromboembolism after thrombolytic treatment: randomized controlled parallel group study. Lung. Springer New York LLC, 2015; Vol. 193, issue 1:121‐7. ">Ucar 2015</a>). </p> <p>One ongoing study has been identified (<a href="./references#CD001100-bbs2-0056" title="NCT00796692 . Nadroparin for the initial treatment of pulmonary thromboembolism (NATSPUTE). ClinicalTrials.gov (first received 20 November 2008). ">NCT00796692</a>). See <a href="./references#CD001100-sec-0104" title="">Characteristics of ongoing studies</a>. </p> </section> </section> <section id="CD001100-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD001100-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD001100-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001100-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD001100-sec-0058"> <h4 class="title">Allocation</h4> <p>Thirteen of the 29 included studies adequately described random sequence generation through the use of a computer or telephone system (<a href="./references#CD001100-bbs2-0003" title="DouketisJD , FosterGA , CrowtherMA , PrinsMH , GinsbergJS . Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine2000;160(22):3431‐6. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep‐vein thrombosis and pulmonary embolism. Blood1996; Vol. 88:626a. The Columbus Investigators. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657‐62. tenCateJW , BüllerHR , GentM , GallusAS , GinsbergJ , PrinsMH , et al. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. Journal of Vascular and Interventional Radiology1998;9:178. ">Columbus 1997</a>; <a href="./references#CD001100-bbs2-0004" title="DecoususH , LeizoroviczA , ParentF , PageY , TardyB , GirardPH , et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep‐vein thrombosis. New England Journal of Medicine1998;338(7):409‐15. ">Decousus 1998</a>; <a href="./references#CD001100-bbs2-0008" title="GoldhaberSZ , MorrisonRB , DiranLL , CreagerMA , LeeTHJr . Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Archives of Internal Medicine1998;158(21):2325‐8. ">Goldhaber 1998</a>; <a href="./references#CD001100-bbs2-0010" title="HullRD , RaskobGE , BrantRF , PineoGF , ElliottG , SteinPD , et al. Low‐molecular‐weight heparin vs heparin in the treatment of patients with pulmonary embolism. American‐Canadian Thrombosis Study Group. Archives of Internal Medicine2000;160(2):229‐36. HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low‐molecular‐weight heparin compared with continuous intravenous heparin in the treatment of proximal‐vein thrombosis. New England Journal of Medicine1992;326(15):975‐82. ">Hull 1992</a>; <a href="./references#CD001100-bbs2-0013" title="KoopmanMMW , PrandoniP , PiovellaF , OckelfordPA , BrandjesDPM , van denMeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low‐molecular‐weight heparin administered at home. New England Journal of Medicine1996;334(11):682‐7. ">Koopman 1996</a>; <a href="./references#CD001100-bbs2-0014" title="LeizoroviczA . Tinzaparin compared to unfractionated heparin for initial treatment of deep vein thrombosis in very elderly patients with renal insufficiency ‐ the IRIS trial. Blood2008; Vol. 112, issue 11:434. LeizoroviczA , SiguretV , MottierD . Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep((R)) in Renal Insufficiency Study (IRIS). Thrombosis Research2011;128(1):27‐34. NCT00277394 . Innohep© in elderly patients with impaired renal function treated for acute deep vein thrombosis. clinicaltrials.gov/ct/show/NCT002773942007. SiguretV , DeudonC , GolmardJ , LeizoroviczA , PautasE , Gouin‐ThibaultI . Pharmacodynamic response to unfractionated heparin used for initial treatment of acute deep vein thrombosis in elderly patients with renal impairment. A substudy of the IRIS clinical trial. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):805. ">Leizorovicz 2011</a>; <a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>; <a href="./references#CD001100-bbs2-0019" title="MerliG , SpiroTE , OlssonCG , AbildgaardU , DavidsonBL , EldorA , et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191‐202. SpiroTE , The Enoxaparin Clinical Trial Group. A multicenter clinical trial comparing once and twice‐daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1997;374(Suppl):Abstract SC 1527. deLissovoyG , YusenRD , SpiroTE , KrupskiWC , ChampionAH , SorensenSV . Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Archives of Internal Medicine2000;160(20):3160‐5. ">Merli 2001</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>; <a href="./references#CD001100-bbs2-0025" title="PrandoniP , CarnovaliM , MarchioriA . Subcutaneous adjusted‐dose unfractionated heparin vs fixed‐dose low‐molecular‐weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164:1077‐83. ">Prandoni 2004</a>; <a href="./references#CD001100-bbs2-0027" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis. Archives of Internal Medicine1993;153(13):1541‐6. ">Simonneau 1993</a>; <a href="./references#CD001100-bbs2-0028" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJ‐P , AzarianR , et al. for the THESEE Study Group. A comparison of low‐molecular‐weight heparin with unfractionated heparin for acute pulmonary embolism. New England Journal of Medicine1997;337(10):663‐9. ">Simonneau 1997</a>). In the remaining 16 studies, there was insufficient information about the random sequence generation to permit a judgement of selection bias. In fourteen of the 29 included studies the assigned treatment was adequately concealed prior to allocation (<a href="./references#CD001100-bbs2-0003" title="DouketisJD , FosterGA , CrowtherMA , PrinsMH , GinsbergJS . Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine2000;160(22):3431‐6. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep‐vein thrombosis and pulmonary embolism. Blood1996; Vol. 88:626a. The Columbus Investigators. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657‐62. tenCateJW , BüllerHR , GentM , GallusAS , GinsbergJ , PrinsMH , et al. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. Journal of Vascular and Interventional Radiology1998;9:178. ">Columbus 1997</a>; <a href="./references#CD001100-bbs2-0004" title="DecoususH , LeizoroviczA , ParentF , PageY , TardyB , GirardPH , et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep‐vein thrombosis. New England Journal of Medicine1998;338(7):409‐15. ">Decousus 1998</a>; <a href="./references#CD001100-bbs2-0008" title="GoldhaberSZ , MorrisonRB , DiranLL , CreagerMA , LeeTHJr . Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Archives of Internal Medicine1998;158(21):2325‐8. ">Goldhaber 1998</a>; <a href="./references#CD001100-bbs2-0010" title="HullRD , RaskobGE , BrantRF , PineoGF , ElliottG , SteinPD , et al. Low‐molecular‐weight heparin vs heparin in the treatment of patients with pulmonary embolism. American‐Canadian Thrombosis Study Group. Archives of Internal Medicine2000;160(2):229‐36. HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low‐molecular‐weight heparin compared with continuous intravenous heparin in the treatment of proximal‐vein thrombosis. New England Journal of Medicine1992;326(15):975‐82. ">Hull 1992</a>; <a href="./references#CD001100-bbs2-0012" title="KirchmaierCM , WolfH , SchaferH , EhlersB , BreddinHK . Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin‐Study Group. International Angiology1998;17(3):135‐45. ">Kirchmaier 1998</a>; <a href="./references#CD001100-bbs2-0013" title="KoopmanMMW , PrandoniP , PiovellaF , OckelfordPA , BrandjesDPM , van denMeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low‐molecular‐weight heparin administered at home. New England Journal of Medicine1996;334(11):682‐7. ">Koopman 1996</a>; <a href="./references#CD001100-bbs2-0015" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low‐molecular‐weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep‐vein thrombosis. New England Journal of Medicine1996;334(11):677‐81. ">Levine 1996</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0019" title="MerliG , SpiroTE , OlssonCG , AbildgaardU , DavidsonBL , EldorA , et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191‐202. SpiroTE , The Enoxaparin Clinical Trial Group. A multicenter clinical trial comparing once and twice‐daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1997;374(Suppl):Abstract SC 1527. deLissovoyG , YusenRD , SpiroTE , KrupskiWC , ChampionAH , SorensenSV . Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Archives of Internal Medicine2000;160(20):3160‐5. ">Merli 2001</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>; <a href="./references#CD001100-bbs2-0025" title="PrandoniP , CarnovaliM , MarchioriA . Subcutaneous adjusted‐dose unfractionated heparin vs fixed‐dose low‐molecular‐weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164:1077‐83. ">Prandoni 2004</a>; <a href="./references#CD001100-bbs2-0026" title="RiessH , KoppenhagenK , TolleA , Kemkes‐MatthesB , GraveM , PatekF , et al. Fixed‐dose, body weight‐independent subcutaneous low molecular weight heparin Certoparin compared with adjusted‐dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thrombosis and Haemostasis2003;90(2):252‐9. RiessH , KoppenhagenK , TolleAR , Kemkes‐MatthesB , GraveM , HarenbergJ , et al. Fixed‐dose body weight‐independent subcutaneous LMW‐heparin (LMWH) certoparin is equally effective to adjusted‐dose intravenous uf‐heparin (UFH) for the initial treatment of proximal deep venous thrombosis (DVT). Annals of Hematology2001;80 Suppl 1:A56. ">Riess 2003</a>; <a href="./references#CD001100-bbs2-0027" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis. Archives of Internal Medicine1993;153(13):1541‐6. ">Simonneau 1993</a>; <a href="./references#CD001100-bbs2-0028" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJ‐P , AzarianR , et al. for the THESEE Study Group. A comparison of low‐molecular‐weight heparin with unfractionated heparin for acute pulmonary embolism. New England Journal of Medicine1997;337(10):663‐9. ">Simonneau 1997</a>), while in the other 14 trials concealment of allocation was unclear, based on the information given in the publication. One study was deemed to be at high risk of selection bias as there was no central allocation (<a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>). Instead, randomisation was conducted separately at each participating centre (see <a href="./references#CD001100-sec-0102" title="">Characteristics of included studies</a>). </p> </section> <section id="CD001100-sec-0059"> <h4 class="title">Blinding</h4> <p>In two of the studies, authors did not state whether the participants and staff were blinded to the treatment or not and therefore the risk of performance bias for these two studies was unclear (<a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0021" title="Moreno‐PalomaresJJ , Fisac‐HerreroRM , Herrero DomingoA , Ferreira‐PasosEM , GrasaJ , Reverte CejudoD . [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis]. Anales de Medicina Interna2001;18(7):364‐8. ">Moreno‐Palomares 2001</a>). In the remaining 27 included studies treatment allocation was not blinded due to the difference in route of administration between subcutaneous LMWH and intravenous UFH. However, given the clinical outcomes of the study, we judged that the non‐blinding of the participants and staff was unlikely to have affected the outcomes and therefore we judged these studies to be at low risk of bias. Even the three studies of subcutaneous UFH versus subcutaneous LMWH were not blinded for treatment allocation due to an initial intravenous bolus in the UFH group (<a href="./references#CD001100-bbs2-0005" title="FaivreR , NeuhartE , KiefferY , ToulemondeF , BassandJP , MauratJP . Subcutaneous administration of a low molecular weight heparin (CY 222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis. Thrombosis and Haemostasis1987;58(1):Abstract 430. FaivreR , NeuhartY , KiefferY , ApfelF , MagninD , DidierD , et al. A new treatment of deep vein thrombosis: low molecular weight heparin fractions. Randomised study [Un nouveau traitement des thromboses veineuses profondes: les fractions d'heparine de bas poids moleculaire. Etude randomisee]. Presse Medicale1988;17(5):197‐200. ">Faivre 1988</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0025" title="PrandoniP , CarnovaliM , MarchioriA . Subcutaneous adjusted‐dose unfractionated heparin vs fixed‐dose low‐molecular‐weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164:1077‐83. ">Prandoni 2004</a>). There was only one double‐blinded clinical trial in which participants received either intravenous UFH with subcutaneous placebo or subcutaneous LMWH with intravenous placebo (<a href="./references#CD001100-bbs2-0010" title="HullRD , RaskobGE , BrantRF , PineoGF , ElliottG , SteinPD , et al. Low‐molecular‐weight heparin vs heparin in the treatment of patients with pulmonary embolism. American‐Canadian Thrombosis Study Group. Archives of Internal Medicine2000;160(2):229‐36. HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low‐molecular‐weight heparin compared with continuous intravenous heparin in the treatment of proximal‐vein thrombosis. New England Journal of Medicine1992;326(15):975‐82. ">Hull 1992</a>). </p> <p>Four of the 29 included studies did not report whether outcome assessors were blinded to treatment and were therefore judged to be at an unclear risk of detection bias (<a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0008" title="GoldhaberSZ , MorrisonRB , DiranLL , CreagerMA , LeeTHJr . Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Archives of Internal Medicine1998;158(21):2325‐8. ">Goldhaber 1998</a>; <a href="./references#CD001100-bbs2-0021" title="Moreno‐PalomaresJJ , Fisac‐HerreroRM , Herrero DomingoA , Ferreira‐PasosEM , GrasaJ , Reverte CejudoD . [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis]. Anales de Medicina Interna2001;18(7):364‐8. ">Moreno‐Palomares 2001</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>). In the remaining 25 studies, outcome assessors were blinded to treatment and therefore these studies were judged to be at low risk of detection bias. </p> </section> <section id="CD001100-sec-0060"> <h4 class="title">Incomplete outcome data</h4> <p>Six studies were judged to be at high risk of attrition bias as data were missing or imbalanced across the groups (<a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>; <a href="./references#CD001100-bbs2-0006" title="FiessingerJN , FernandezML , GattererE , OhlssonCG . Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial. Haemostasis1994;24(Suppl 1):Abstract 44. FiessingerJN , Lopez‐FernandezM , GattererE , GranqvistS , KherA , OlssonCG , et al. Once‐daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1996;76(2):195‐9. ">Fiessinger 1996</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0022" title="NinetJ , BachetP , PrandoniP , RuolA , VigoM , BarretA , et al. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1991;65(3):251‐6. ">Ninet 1991</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>); 18 were judged to be at low risk (<a href="./references#CD001100-bbs2-0001" title="BelcaroG , NicolaidesAN , CesaroneMR , LauroraG , DeSanctisMT , IncandelaL , et al. Comparison of low‐molecular‐weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep‐vein thrombosis. Angiology1999;50(10):781‐7. ">Belcaro 1999</a>; <a href="./references#CD001100-bbs2-0003" title="DouketisJD , FosterGA , CrowtherMA , PrinsMH , GinsbergJS . Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine2000;160(22):3431‐6. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep‐vein thrombosis and pulmonary embolism. Blood1996; Vol. 88:626a. The Columbus Investigators. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657‐62. tenCateJW , BüllerHR , GentM , GallusAS , GinsbergJ , PrinsMH , et al. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. Journal of Vascular and Interventional Radiology1998;9:178. ">Columbus 1997</a>; <a href="./references#CD001100-bbs2-0004" title="DecoususH , LeizoroviczA , ParentF , PageY , TardyB , GirardPH , et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep‐vein thrombosis. New England Journal of Medicine1998;338(7):409‐15. ">Decousus 1998</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0010" title="HullRD , RaskobGE , BrantRF , PineoGF , ElliottG , SteinPD , et al. Low‐molecular‐weight heparin vs heparin in the treatment of patients with pulmonary embolism. American‐Canadian Thrombosis Study Group. Archives of Internal Medicine2000;160(2):229‐36. HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low‐molecular‐weight heparin compared with continuous intravenous heparin in the treatment of proximal‐vein thrombosis. New England Journal of Medicine1992;326(15):975‐82. ">Hull 1992</a>; <a href="./references#CD001100-bbs2-0013" title="KoopmanMMW , PrandoniP , PiovellaF , OckelfordPA , BrandjesDPM , van denMeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low‐molecular‐weight heparin administered at home. New England Journal of Medicine1996;334(11):682‐7. ">Koopman 1996</a>; <a href="./references#CD001100-bbs2-0014" title="LeizoroviczA . Tinzaparin compared to unfractionated heparin for initial treatment of deep vein thrombosis in very elderly patients with renal insufficiency ‐ the IRIS trial. Blood2008; Vol. 112, issue 11:434. LeizoroviczA , SiguretV , MottierD . Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep((R)) in Renal Insufficiency Study (IRIS). Thrombosis Research2011;128(1):27‐34. NCT00277394 . Innohep© in elderly patients with impaired renal function treated for acute deep vein thrombosis. clinicaltrials.gov/ct/show/NCT002773942007. SiguretV , DeudonC , GolmardJ , LeizoroviczA , PautasE , Gouin‐ThibaultI . Pharmacodynamic response to unfractionated heparin used for initial treatment of acute deep vein thrombosis in elderly patients with renal impairment. A substudy of the IRIS clinical trial. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):805. ">Leizorovicz 2011</a>; <a href="./references#CD001100-bbs2-0015" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low‐molecular‐weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep‐vein thrombosis. New England Journal of Medicine1996;334(11):677‐81. ">Levine 1996</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>; <a href="./references#CD001100-bbs2-0019" title="MerliG , SpiroTE , OlssonCG , AbildgaardU , DavidsonBL , EldorA , et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191‐202. SpiroTE , The Enoxaparin Clinical Trial Group. A multicenter clinical trial comparing once and twice‐daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1997;374(Suppl):Abstract SC 1527. deLissovoyG , YusenRD , SpiroTE , KrupskiWC , ChampionAH , SorensenSV . Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Archives of Internal Medicine2000;160(20):3160‐5. ">Merli 2001</a>; <a href="./references#CD001100-bbs2-0020" title="MeyerG , BrenotF , PacouretG , SimonneauG , Gillet JuvinK , CharbonnierB , et al. Subcutaneous low‐molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thrombosis and Haemostasis1995;74(6):1432‐5. ">Meyer 1995</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>; <a href="./references#CD001100-bbs2-0025" title="PrandoniP , CarnovaliM , MarchioriA . Subcutaneous adjusted‐dose unfractionated heparin vs fixed‐dose low‐molecular‐weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164:1077‐83. ">Prandoni 2004</a>; <a href="./references#CD001100-bbs2-0026" title="RiessH , KoppenhagenK , TolleA , Kemkes‐MatthesB , GraveM , PatekF , et al. Fixed‐dose, body weight‐independent subcutaneous low molecular weight heparin Certoparin compared with adjusted‐dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thrombosis and Haemostasis2003;90(2):252‐9. RiessH , KoppenhagenK , TolleAR , Kemkes‐MatthesB , GraveM , HarenbergJ , et al. Fixed‐dose body weight‐independent subcutaneous LMW‐heparin (LMWH) certoparin is equally effective to adjusted‐dose intravenous uf‐heparin (UFH) for the initial treatment of proximal deep venous thrombosis (DVT). Annals of Hematology2001;80 Suppl 1:A56. ">Riess 2003</a>; <a href="./references#CD001100-bbs2-0027" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis. Archives of Internal Medicine1993;153(13):1541‐6. ">Simonneau 1993</a>; <a href="./references#CD001100-bbs2-0028" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJ‐P , AzarianR , et al. for the THESEE Study Group. A comparison of low‐molecular‐weight heparin with unfractionated heparin for acute pulmonary embolism. New England Journal of Medicine1997;337(10):663‐9. ">Simonneau 1997</a>); while five did not provide enough information to permit a judgement (<a href="./references#CD001100-bbs2-0005" title="FaivreR , NeuhartE , KiefferY , ToulemondeF , BassandJP , MauratJP . Subcutaneous administration of a low molecular weight heparin (CY 222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis. Thrombosis and Haemostasis1987;58(1):Abstract 430. FaivreR , NeuhartY , KiefferY , ApfelF , MagninD , DidierD , et al. A new treatment of deep vein thrombosis: low molecular weight heparin fractions. Randomised study [Un nouveau traitement des thromboses veineuses profondes: les fractions d'heparine de bas poids moleculaire. Etude randomisee]. Presse Medicale1988;17(5):197‐200. ">Faivre 1988</a>; <a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0008" title="GoldhaberSZ , MorrisonRB , DiranLL , CreagerMA , LeeTHJr . Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Archives of Internal Medicine1998;158(21):2325‐8. ">Goldhaber 1998</a>; <a href="./references#CD001100-bbs2-0012" title="KirchmaierCM , WolfH , SchaferH , EhlersB , BreddinHK . Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin‐Study Group. International Angiology1998;17(3):135‐45. ">Kirchmaier 1998</a>; <a href="./references#CD001100-bbs2-0021" title="Moreno‐PalomaresJJ , Fisac‐HerreroRM , Herrero DomingoA , Ferreira‐PasosEM , GrasaJ , Reverte CejudoD . [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis]. Anales de Medicina Interna2001;18(7):364‐8. ">Moreno‐Palomares 2001</a>). </p> </section> <section id="CD001100-sec-0061"> <h4 class="title">Selective reporting</h4> <p>Two studies were judged to be at high risk of reporting bias (<a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>). In the study by <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>, participants who had died or had a VTE were not included in the analysis. In the study by <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>, length of stay was not a prespecified outcome but authors reported data on it in the discussion. Twenty‐two studies were at low risk while the remaining five did not provide enough information to permit judgement on reporting bias (<a href="./references#CD001100-bbs2-0005" title="FaivreR , NeuhartE , KiefferY , ToulemondeF , BassandJP , MauratJP . Subcutaneous administration of a low molecular weight heparin (CY 222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis. Thrombosis and Haemostasis1987;58(1):Abstract 430. FaivreR , NeuhartY , KiefferY , ApfelF , MagninD , DidierD , et al. A new treatment of deep vein thrombosis: low molecular weight heparin fractions. Randomised study [Un nouveau traitement des thromboses veineuses profondes: les fractions d'heparine de bas poids moleculaire. Etude randomisee]. Presse Medicale1988;17(5):197‐200. ">Faivre 1988</a>; <a href="./references#CD001100-bbs2-0006" title="FiessingerJN , FernandezML , GattererE , OhlssonCG . Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial. Haemostasis1994;24(Suppl 1):Abstract 44. FiessingerJN , Lopez‐FernandezM , GattererE , GranqvistS , KherA , OlssonCG , et al. Once‐daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1996;76(2):195‐9. ">Fiessinger 1996</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0021" title="Moreno‐PalomaresJJ , Fisac‐HerreroRM , Herrero DomingoA , Ferreira‐PasosEM , GrasaJ , Reverte CejudoD . [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis]. Anales de Medicina Interna2001;18(7):364‐8. ">Moreno‐Palomares 2001</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>). </p> </section> <section id="CD001100-sec-0062"> <h4 class="title">Other potential sources of bias</h4> <p>Five studies were judged to be at high risk of bias (<a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>). Two studies were sponsored by the pharmaceutical companies that provided the study drug (<a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>). The study by <a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a> had a low statistical power due to low numbers of participants and few outcome events. <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a> had an imbalance in exclusion of participants at baseline while the study by <a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a> had a higher incidence of malignancy in participants treated with UFH. Twenty studies were judged to be free from other sources of bias; while in the remaining four, there was not enough information to permit judgement (<a href="./references#CD001100-bbs2-0004" title="DecoususH , LeizoroviczA , ParentF , PageY , TardyB , GirardPH , et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep‐vein thrombosis. New England Journal of Medicine1998;338(7):409‐15. ">Decousus 1998</a>; <a href="./references#CD001100-bbs2-0005" title="FaivreR , NeuhartE , KiefferY , ToulemondeF , BassandJP , MauratJP . Subcutaneous administration of a low molecular weight heparin (CY 222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis. Thrombosis and Haemostasis1987;58(1):Abstract 430. FaivreR , NeuhartY , KiefferY , ApfelF , MagninD , DidierD , et al. A new treatment of deep vein thrombosis: low molecular weight heparin fractions. Randomised study [Un nouveau traitement des thromboses veineuses profondes: les fractions d'heparine de bas poids moleculaire. Etude randomisee]. Presse Medicale1988;17(5):197‐200. ">Faivre 1988</a>; <a href="./references#CD001100-bbs2-0014" title="LeizoroviczA . Tinzaparin compared to unfractionated heparin for initial treatment of deep vein thrombosis in very elderly patients with renal insufficiency ‐ the IRIS trial. Blood2008; Vol. 112, issue 11:434. LeizoroviczA , SiguretV , MottierD . Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep((R)) in Renal Insufficiency Study (IRIS). Thrombosis Research2011;128(1):27‐34. NCT00277394 . Innohep© in elderly patients with impaired renal function treated for acute deep vein thrombosis. clinicaltrials.gov/ct/show/NCT002773942007. SiguretV , DeudonC , GolmardJ , LeizoroviczA , PautasE , Gouin‐ThibaultI . Pharmacodynamic response to unfractionated heparin used for initial treatment of acute deep vein thrombosis in elderly patients with renal impairment. A substudy of the IRIS clinical trial. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):805. ">Leizorovicz 2011</a>; <a href="./references#CD001100-bbs2-0021" title="Moreno‐PalomaresJJ , Fisac‐HerreroRM , Herrero DomingoA , Ferreira‐PasosEM , GrasaJ , Reverte CejudoD . [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis]. Anales de Medicina Interna2001;18(7):364‐8. ">Moreno‐Palomares 2001</a>). </p> </section> </section> <section id="CD001100-sec-0063"> <h3 class="title" id="CD001100-sec-0063">Effects of interventions</h3> <p>See: <a href="./full#CD001100-tbl-0001"><b>Summary of findings for the main comparison</b> LMWH compared to UFH for initial treatment of venous thromboembolism</a> </p> <p>None of the trials individually demonstrated protection from recurrent symptomatic venous thromboembolic complications during the initial treatment period. One trial showed that LMWH conferred protection from recurrent symptomatic venous thromboembolic complications at the end of follow‐up (<a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>). Only <a href="./references#CD001100-bbs2-0010" title="HullRD , RaskobGE , BrantRF , PineoGF , ElliottG , SteinPD , et al. Low‐molecular‐weight heparin vs heparin in the treatment of patients with pulmonary embolism. American‐Canadian Thrombosis Study Group. Archives of Internal Medicine2000;160(2):229‐36. HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low‐molecular‐weight heparin compared with continuous intravenous heparin in the treatment of proximal‐vein thrombosis. New England Journal of Medicine1992;326(15):975‐82. ">Hull 1992</a> demonstrated a reduction in major haemorrhage after treatment with LMWH. Six studies showed a reduction in thrombus size, between pre‐treatment and post‐treatment venograms, in favour of LMWH (<a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>; <a href="./references#CD001100-bbs2-0008" title="GoldhaberSZ , MorrisonRB , DiranLL , CreagerMA , LeeTHJr . Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Archives of Internal Medicine1998;158(21):2325‐8. ">Goldhaber 1998</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>; <a href="./references#CD001100-bbs2-0027" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis. Archives of Internal Medicine1993;153(13):1541‐6. ">Simonneau 1993</a>). </p> <section id="CD001100-sec-0064"> <h4 class="title">Incidence of symptomatic recurrent venous thromboembolism (Analysis 1.1 to Analysis 1.5) ('Summary of findings' table 1) </h4> <p>The occurrence of symptomatic recurrent venous thromboembolism was evaluated during the initial treatment period (<a href="./references#CD001100-bbs2-0003" title="DouketisJD , FosterGA , CrowtherMA , PrinsMH , GinsbergJS . Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine2000;160(22):3431‐6. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep‐vein thrombosis and pulmonary embolism. Blood1996; Vol. 88:626a. The Columbus Investigators. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657‐62. tenCateJW , BüllerHR , GentM , GallusAS , GinsbergJ , PrinsMH , et al. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. Journal of Vascular and Interventional Radiology1998;9:178. ">Columbus 1997</a>; <a href="./references#CD001100-bbs2-0004" title="DecoususH , LeizoroviczA , ParentF , PageY , TardyB , GirardPH , et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep‐vein thrombosis. New England Journal of Medicine1998;338(7):409‐15. ">Decousus 1998</a>; <a href="./references#CD001100-bbs2-0006" title="FiessingerJN , FernandezML , GattererE , OhlssonCG . Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial. Haemostasis1994;24(Suppl 1):Abstract 44. FiessingerJN , Lopez‐FernandezM , GattererE , GranqvistS , KherA , OlssonCG , et al. Once‐daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1996;76(2):195‐9. ">Fiessinger 1996</a>; <a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0012" title="KirchmaierCM , WolfH , SchaferH , EhlersB , BreddinHK . Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin‐Study Group. International Angiology1998;17(3):135‐45. ">Kirchmaier 1998</a>; <a href="./references#CD001100-bbs2-0013" title="KoopmanMMW , PrandoniP , PiovellaF , OckelfordPA , BrandjesDPM , van denMeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low‐molecular‐weight heparin administered at home. New England Journal of Medicine1996;334(11):682‐7. ">Koopman 1996</a>; <a href="./references#CD001100-bbs2-0015" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low‐molecular‐weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep‐vein thrombosis. New England Journal of Medicine1996;334(11):677‐81. ">Levine 1996</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0020" title="MeyerG , BrenotF , PacouretG , SimonneauG , Gillet JuvinK , CharbonnierB , et al. Subcutaneous low‐molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thrombosis and Haemostasis1995;74(6):1432‐5. ">Meyer 1995</a>; <a href="./references#CD001100-bbs2-0022" title="NinetJ , BachetP , PrandoniP , RuolA , VigoM , BarretA , et al. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1991;65(3):251‐6. ">Ninet 1991</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>; <a href="./references#CD001100-bbs2-0026" title="RiessH , KoppenhagenK , TolleA , Kemkes‐MatthesB , GraveM , PatekF , et al. Fixed‐dose, body weight‐independent subcutaneous low molecular weight heparin Certoparin compared with adjusted‐dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thrombosis and Haemostasis2003;90(2):252‐9. RiessH , KoppenhagenK , TolleAR , Kemkes‐MatthesB , GraveM , HarenbergJ , et al. Fixed‐dose body weight‐independent subcutaneous LMW‐heparin (LMWH) certoparin is equally effective to adjusted‐dose intravenous uf‐heparin (UFH) for the initial treatment of proximal deep venous thrombosis (DVT). Annals of Hematology2001;80 Suppl 1:A56. ">Riess 2003</a>; <a href="./references#CD001100-bbs2-0027" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis. Archives of Internal Medicine1993;153(13):1541‐6. ">Simonneau 1993</a>; <a href="./references#CD001100-bbs2-0028" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJ‐P , AzarianR , et al. for the THESEE Study Group. A comparison of low‐molecular‐weight heparin with unfractionated heparin for acute pulmonary embolism. New England Journal of Medicine1997;337(10):663‐9. ">Simonneau 1997</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>); at one month's follow‐up (<a href="./references#CD001100-bbs2-0003" title="DouketisJD , FosterGA , CrowtherMA , PrinsMH , GinsbergJS . Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine2000;160(22):3431‐6. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep‐vein thrombosis and pulmonary embolism. Blood1996; Vol. 88:626a. The Columbus Investigators. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657‐62. tenCateJW , BüllerHR , GentM , GallusAS , GinsbergJ , PrinsMH , et al. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. Journal of Vascular and Interventional Radiology1998;9:178. ">Columbus 1997</a>; <a href="./references#CD001100-bbs2-0015" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low‐molecular‐weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep‐vein thrombosis. New England Journal of Medicine1996;334(11):677‐81. ">Levine 1996</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>); at three months' follow‐up (<a href="./references#CD001100-bbs2-0001" title="BelcaroG , NicolaidesAN , CesaroneMR , LauroraG , DeSanctisMT , IncandelaL , et al. Comparison of low‐molecular‐weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep‐vein thrombosis. Angiology1999;50(10):781‐7. ">Belcaro 1999</a>; <a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>; <a href="./references#CD001100-bbs2-0003" title="DouketisJD , FosterGA , CrowtherMA , PrinsMH , GinsbergJS . Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine2000;160(22):3431‐6. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep‐vein thrombosis and pulmonary embolism. Blood1996; Vol. 88:626a. The Columbus Investigators. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657‐62. tenCateJW , BüllerHR , GentM , GallusAS , GinsbergJ , PrinsMH , et al. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. Journal of Vascular and Interventional Radiology1998;9:178. ">Columbus 1997</a>; <a href="./references#CD001100-bbs2-0004" title="DecoususH , LeizoroviczA , ParentF , PageY , TardyB , GirardPH , et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep‐vein thrombosis. New England Journal of Medicine1998;338(7):409‐15. ">Decousus 1998</a>; <a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0010" title="HullRD , RaskobGE , BrantRF , PineoGF , ElliottG , SteinPD , et al. Low‐molecular‐weight heparin vs heparin in the treatment of patients with pulmonary embolism. American‐Canadian Thrombosis Study Group. Archives of Internal Medicine2000;160(2):229‐36. HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low‐molecular‐weight heparin compared with continuous intravenous heparin in the treatment of proximal‐vein thrombosis. New England Journal of Medicine1992;326(15):975‐82. ">Hull 1992</a>; <a href="./references#CD001100-bbs2-0013" title="KoopmanMMW , PrandoniP , PiovellaF , OckelfordPA , BrandjesDPM , van denMeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low‐molecular‐weight heparin administered at home. New England Journal of Medicine1996;334(11):682‐7. ">Koopman 1996</a>; <a href="./references#CD001100-bbs2-0015" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low‐molecular‐weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep‐vein thrombosis. New England Journal of Medicine1996;334(11):677‐81. ">Levine 1996</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0019" title="MerliG , SpiroTE , OlssonCG , AbildgaardU , DavidsonBL , EldorA , et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191‐202. SpiroTE , The Enoxaparin Clinical Trial Group. A multicenter clinical trial comparing once and twice‐daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1997;374(Suppl):Abstract SC 1527. deLissovoyG , YusenRD , SpiroTE , KrupskiWC , ChampionAH , SorensenSV . Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Archives of Internal Medicine2000;160(20):3160‐5. ">Merli 2001</a>; <a href="./references#CD001100-bbs2-0020" title="MeyerG , BrenotF , PacouretG , SimonneauG , Gillet JuvinK , CharbonnierB , et al. Subcutaneous low‐molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thrombosis and Haemostasis1995;74(6):1432‐5. ">Meyer 1995</a>; <a href="./references#CD001100-bbs2-0021" title="Moreno‐PalomaresJJ , Fisac‐HerreroRM , Herrero DomingoA , Ferreira‐PasosEM , GrasaJ , Reverte CejudoD . [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis]. Anales de Medicina Interna2001;18(7):364‐8. ">Moreno‐Palomares 2001</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>; <a href="./references#CD001100-bbs2-0025" title="PrandoniP , CarnovaliM , MarchioriA . Subcutaneous adjusted‐dose unfractionated heparin vs fixed‐dose low‐molecular‐weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164:1077‐83. ">Prandoni 2004</a>; <a href="./references#CD001100-bbs2-0027" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis. Archives of Internal Medicine1993;153(13):1541‐6. ">Simonneau 1993</a>; <a href="./references#CD001100-bbs2-0028" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJ‐P , AzarianR , et al. for the THESEE Study Group. A comparison of low‐molecular‐weight heparin with unfractionated heparin for acute pulmonary embolism. New England Journal of Medicine1997;337(10):663‐9. ">Simonneau 1997</a>); and at six months' follow‐up (<a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0012" title="KirchmaierCM , WolfH , SchaferH , EhlersB , BreddinHK . Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin‐Study Group. International Angiology1998;17(3):135‐45. ">Kirchmaier 1998</a>; <a href="./references#CD001100-bbs2-0013" title="KoopmanMMW , PrandoniP , PiovellaF , OckelfordPA , BrandjesDPM , van denMeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low‐molecular‐weight heparin administered at home. New England Journal of Medicine1996;334(11):682‐7. ">Koopman 1996</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>; <a href="./references#CD001100-bbs2-0026" title="RiessH , KoppenhagenK , TolleA , Kemkes‐MatthesB , GraveM , PatekF , et al. Fixed‐dose, body weight‐independent subcutaneous low molecular weight heparin Certoparin compared with adjusted‐dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thrombosis and Haemostasis2003;90(2):252‐9. RiessH , KoppenhagenK , TolleAR , Kemkes‐MatthesB , GraveM , HarenbergJ , et al. Fixed‐dose body weight‐independent subcutaneous LMW‐heparin (LMWH) certoparin is equally effective to adjusted‐dose intravenous uf‐heparin (UFH) for the initial treatment of proximal deep venous thrombosis (DVT). Annals of Hematology2001;80 Suppl 1:A56. ">Riess 2003</a>). Combining all trials with long‐term follow‐up gave a comparison of recurrent thromboembolism at the end of follow‐up. Although <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a> reported incidence of recurrent VTE, there was a query regarding the exact number of participants reported to have this outcome. The author was contacted to clarify the data but did not respond and therefore this study was not included in the analysis. </p> <p>Analysis of the pooled data from these studies demonstrated a reduction in recurrent venous thromboembolic events with LMWH during the initial treatment period (Peto OR 0.69, 95% CI 0.49 to 0.98; moderate‐quality evidence; participants = 6238; studies = 18; P = 0.04); at the end of follow‐up (Peto OR 0.72, 95% CI 0.59 to 0.88; participants = 9489; studies = 22; P = 0.0005), at three months' follow‐up (Peto OR 0.71, 95% CI 0.56 to 0.90; moderate‐quality evidence; participants = 6661; studies = 16; P = 0.005); and at six months' follow‐up (Peto OR 0.68, 95% CI 0.48 to 0.96; participants = 2841; studies = 7; P = 0.03). However, at one month's follow‐up, no difference was found between LMWH and UFH (Peto OR 0.90, 95% CI 0.56 to 1.44; participants = 1741; studies = 4; P = 0.65). </p> <p>During the initial treatment, 54 (1.7%) of the 3123 participants allocated to LMWH had thrombotic complications versus 76 (2.4%) of the 3115 participants allocated to UFH. After a follow‐up of three months, the period in most of the studies for which oral anticoagulant therapy was given, 122 (3.5%) of the 3440 participants treated with LMWH had a recurrent thrombotic event versus 164 (5.2%) of the 3221 participants treated with UFH. </p> <p>When different preparations of heparin were compared, a reduction in recurrent VTE was noted during the initial treatment period for enoxaparin (Peto OR 0.51, 95% CI 0.27 to 0.98; participants = 1143; studies = 5; P = 0.04) and at the end of follow‐up for certoparin (Peto OR 0.63, 95% CI 0.40 to 0.99; participants = 2007; 3 studies; P = 0.05) versus UFH. Overall, no differences were observed between the heparin preparations during the initial treatment period and at the end of follow‐up. </p> </section> <section id="CD001100-sec-0065"> <h4 class="title">Reduction in thrombus size (Analysis 1.6)</h4> <p>Venograms were obtained before and after heparin treatment in 16 studies (<a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>; <a href="./references#CD001100-bbs2-0005" title="FaivreR , NeuhartE , KiefferY , ToulemondeF , BassandJP , MauratJP . Subcutaneous administration of a low molecular weight heparin (CY 222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis. Thrombosis and Haemostasis1987;58(1):Abstract 430. FaivreR , NeuhartY , KiefferY , ApfelF , MagninD , DidierD , et al. A new treatment of deep vein thrombosis: low molecular weight heparin fractions. Randomised study [Un nouveau traitement des thromboses veineuses profondes: les fractions d'heparine de bas poids moleculaire. Etude randomisee]. Presse Medicale1988;17(5):197‐200. ">Faivre 1988</a>; <a href="./references#CD001100-bbs2-0006" title="FiessingerJN , FernandezML , GattererE , OhlssonCG . Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial. Haemostasis1994;24(Suppl 1):Abstract 44. FiessingerJN , Lopez‐FernandezM , GattererE , GranqvistS , KherA , OlssonCG , et al. Once‐daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1996;76(2):195‐9. ">Fiessinger 1996</a>; <a href="./references#CD001100-bbs2-0008" title="GoldhaberSZ , MorrisonRB , DiranLL , CreagerMA , LeeTHJr . Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Archives of Internal Medicine1998;158(21):2325‐8. ">Goldhaber 1998</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0012" title="KirchmaierCM , WolfH , SchaferH , EhlersB , BreddinHK . Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin‐Study Group. International Angiology1998;17(3):135‐45. ">Kirchmaier 1998</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>; <a href="./references#CD001100-bbs2-0020" title="MeyerG , BrenotF , PacouretG , SimonneauG , Gillet JuvinK , CharbonnierB , et al. Subcutaneous low‐molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thrombosis and Haemostasis1995;74(6):1432‐5. ">Meyer 1995</a>; <a href="./references#CD001100-bbs2-0021" title="Moreno‐PalomaresJJ , Fisac‐HerreroRM , Herrero DomingoA , Ferreira‐PasosEM , GrasaJ , Reverte CejudoD . [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis]. Anales de Medicina Interna2001;18(7):364‐8. ">Moreno‐Palomares 2001</a>; <a href="./references#CD001100-bbs2-0022" title="NinetJ , BachetP , PrandoniP , RuolA , VigoM , BarretA , et al. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1991;65(3):251‐6. ">Ninet 1991</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>; <a href="./references#CD001100-bbs2-0027" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis. Archives of Internal Medicine1993;153(13):1541‐6. ">Simonneau 1993</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>). In all studies these venograms were adjudicated by investigators unaware of treatment allocation. The combined results of the 16 studies demonstrated a reduction of thrombus size in 51% of the participants (741 out of 1467) treated with LMWH and in 42% of participants (610 out of 1442) treated with UFH. LMWH was associated with a reduction in thrombus size compared with UFH (Peto OR 0.71, 95% CI 0.61 to 0.82; moderate‐quality evidence; participants = 2909; studies = 16; P &lt; 0.00001). However there was moderate heterogeneity in this analysis (I² = 56%). When we performed analysis by studies reporting on DVT, the heterogeneity was reduced (I² = 34%) (<a href="./references#CD001100-fig-0017" title="">Analysis 2.4</a>). See also below. </p> <p>Subgroup analysis showed a difference between the LMWH preparations (P = 0.004). Of the individual LMWH preparations, a better venographic outcome was observed for ardeparin (Peto OR 0.37, 95% CI 0.14 to 0.99), enoxaparin (Peto OR 0.34, 95% CI 0.17 to 0.71), reviparin (Peto OR 0.59, 95% CI 0.43 to 0.80), certoparin (Peto OR 0.70, 95% CI 0.50 to 0.98) and bemiparin (Peto OR 0.42, 95% CI 0.24 to 0.74). </p> </section> <section id="CD001100-sec-0066"> <h4 class="title">Incidence of major haemorrhage during the initial treatment (Analysis 1.7)</h4> <p>Twenty‐five of the included trials evaluated the occurrence of major haemorrhage during the initial treatment (<a href="./references#CD001100-bbs2-0001" title="BelcaroG , NicolaidesAN , CesaroneMR , LauroraG , DeSanctisMT , IncandelaL , et al. Comparison of low‐molecular‐weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep‐vein thrombosis. Angiology1999;50(10):781‐7. ">Belcaro 1999</a>; <a href="./references#CD001100-bbs2-0003" title="DouketisJD , FosterGA , CrowtherMA , PrinsMH , GinsbergJS . Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine2000;160(22):3431‐6. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep‐vein thrombosis and pulmonary embolism. Blood1996; Vol. 88:626a. The Columbus Investigators. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657‐62. tenCateJW , BüllerHR , GentM , GallusAS , GinsbergJ , PrinsMH , et al. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. Journal of Vascular and Interventional Radiology1998;9:178. ">Columbus 1997</a>; <a href="./references#CD001100-bbs2-0004" title="DecoususH , LeizoroviczA , ParentF , PageY , TardyB , GirardPH , et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep‐vein thrombosis. New England Journal of Medicine1998;338(7):409‐15. ">Decousus 1998</a>; <a href="./references#CD001100-bbs2-0005" title="FaivreR , NeuhartE , KiefferY , ToulemondeF , BassandJP , MauratJP . Subcutaneous administration of a low molecular weight heparin (CY 222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis. Thrombosis and Haemostasis1987;58(1):Abstract 430. FaivreR , NeuhartY , KiefferY , ApfelF , MagninD , DidierD , et al. A new treatment of deep vein thrombosis: low molecular weight heparin fractions. Randomised study [Un nouveau traitement des thromboses veineuses profondes: les fractions d'heparine de bas poids moleculaire. Etude randomisee]. Presse Medicale1988;17(5):197‐200. ">Faivre 1988</a>; <a href="./references#CD001100-bbs2-0006" title="FiessingerJN , FernandezML , GattererE , OhlssonCG . Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial. Haemostasis1994;24(Suppl 1):Abstract 44. FiessingerJN , Lopez‐FernandezM , GattererE , GranqvistS , KherA , OlssonCG , et al. Once‐daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1996;76(2):195‐9. ">Fiessinger 1996</a>; <a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0010" title="HullRD , RaskobGE , BrantRF , PineoGF , ElliottG , SteinPD , et al. Low‐molecular‐weight heparin vs heparin in the treatment of patients with pulmonary embolism. American‐Canadian Thrombosis Study Group. Archives of Internal Medicine2000;160(2):229‐36. HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low‐molecular‐weight heparin compared with continuous intravenous heparin in the treatment of proximal‐vein thrombosis. New England Journal of Medicine1992;326(15):975‐82. ">Hull 1992</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0012" title="KirchmaierCM , WolfH , SchaferH , EhlersB , BreddinHK . Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin‐Study Group. International Angiology1998;17(3):135‐45. ">Kirchmaier 1998</a>; <a href="./references#CD001100-bbs2-0013" title="KoopmanMMW , PrandoniP , PiovellaF , OckelfordPA , BrandjesDPM , van denMeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low‐molecular‐weight heparin administered at home. New England Journal of Medicine1996;334(11):682‐7. ">Koopman 1996</a>; <a href="./references#CD001100-bbs2-0014" title="LeizoroviczA . Tinzaparin compared to unfractionated heparin for initial treatment of deep vein thrombosis in very elderly patients with renal insufficiency ‐ the IRIS trial. Blood2008; Vol. 112, issue 11:434. LeizoroviczA , SiguretV , MottierD . Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep((R)) in Renal Insufficiency Study (IRIS). Thrombosis Research2011;128(1):27‐34. NCT00277394 . Innohep© in elderly patients with impaired renal function treated for acute deep vein thrombosis. clinicaltrials.gov/ct/show/NCT002773942007. SiguretV , DeudonC , GolmardJ , LeizoroviczA , PautasE , Gouin‐ThibaultI . Pharmacodynamic response to unfractionated heparin used for initial treatment of acute deep vein thrombosis in elderly patients with renal impairment. A substudy of the IRIS clinical trial. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):805. ">Leizorovicz 2011</a>; <a href="./references#CD001100-bbs2-0015" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low‐molecular‐weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep‐vein thrombosis. New England Journal of Medicine1996;334(11):677‐81. ">Levine 1996</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>; <a href="./references#CD001100-bbs2-0020" title="MeyerG , BrenotF , PacouretG , SimonneauG , Gillet JuvinK , CharbonnierB , et al. Subcutaneous low‐molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thrombosis and Haemostasis1995;74(6):1432‐5. ">Meyer 1995</a>; <a href="./references#CD001100-bbs2-0022" title="NinetJ , BachetP , PrandoniP , RuolA , VigoM , BarretA , et al. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1991;65(3):251‐6. ">Ninet 1991</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>; <a href="./references#CD001100-bbs2-0025" title="PrandoniP , CarnovaliM , MarchioriA . Subcutaneous adjusted‐dose unfractionated heparin vs fixed‐dose low‐molecular‐weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164:1077‐83. ">Prandoni 2004</a>; <a href="./references#CD001100-bbs2-0026" title="RiessH , KoppenhagenK , TolleA , Kemkes‐MatthesB , GraveM , PatekF , et al. Fixed‐dose, body weight‐independent subcutaneous low molecular weight heparin Certoparin compared with adjusted‐dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thrombosis and Haemostasis2003;90(2):252‐9. RiessH , KoppenhagenK , TolleAR , Kemkes‐MatthesB , GraveM , HarenbergJ , et al. Fixed‐dose body weight‐independent subcutaneous LMW‐heparin (LMWH) certoparin is equally effective to adjusted‐dose intravenous uf‐heparin (UFH) for the initial treatment of proximal deep venous thrombosis (DVT). Annals of Hematology2001;80 Suppl 1:A56. ">Riess 2003</a>; <a href="./references#CD001100-bbs2-0027" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis. Archives of Internal Medicine1993;153(13):1541‐6. ">Simonneau 1993</a>; <a href="./references#CD001100-bbs2-0028" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJ‐P , AzarianR , et al. for the THESEE Study Group. A comparison of low‐molecular‐weight heparin with unfractionated heparin for acute pulmonary embolism. New England Journal of Medicine1997;337(10):663‐9. ">Simonneau 1997</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>). Analysis of the pooled data showed a reduction in major haemorrhagic complications in favour of LMWH (Peto OR 0.69, 95% CI 0.50 to 0.95; participants = 8780; studies = 25; moderate‐quality evidence; P = 0.02). At the end of the initial treatment period, 65 (1.5%) of the 4333 participants in the LMWH group versus 94 (2.1%) of the 4447 participants in the UFH group suffered a major haemorrhage. </p> <p>Subgroup analysis showed no difference between the LMWH preparations (P = 0.10).</p> </section> <section id="CD001100-sec-0067"> <h4 class="title">Overall mortality at the end of follow‐up (Analysis 1.8)</h4> <p>Twenty‐four studies prospectively evaluated the overall mortality at the end of follow‐up (<a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>; <a href="./references#CD001100-bbs2-0003" title="DouketisJD , FosterGA , CrowtherMA , PrinsMH , GinsbergJS . Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine2000;160(22):3431‐6. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep‐vein thrombosis and pulmonary embolism. Blood1996; Vol. 88:626a. The Columbus Investigators. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657‐62. tenCateJW , BüllerHR , GentM , GallusAS , GinsbergJ , PrinsMH , et al. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. Journal of Vascular and Interventional Radiology1998;9:178. ">Columbus 1997</a>; <a href="./references#CD001100-bbs2-0004" title="DecoususH , LeizoroviczA , ParentF , PageY , TardyB , GirardPH , et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep‐vein thrombosis. New England Journal of Medicine1998;338(7):409‐15. ">Decousus 1998</a>; <a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0008" title="GoldhaberSZ , MorrisonRB , DiranLL , CreagerMA , LeeTHJr . Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Archives of Internal Medicine1998;158(21):2325‐8. ">Goldhaber 1998</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0010" title="HullRD , RaskobGE , BrantRF , PineoGF , ElliottG , SteinPD , et al. Low‐molecular‐weight heparin vs heparin in the treatment of patients with pulmonary embolism. American‐Canadian Thrombosis Study Group. Archives of Internal Medicine2000;160(2):229‐36. HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low‐molecular‐weight heparin compared with continuous intravenous heparin in the treatment of proximal‐vein thrombosis. New England Journal of Medicine1992;326(15):975‐82. ">Hull 1992</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0012" title="KirchmaierCM , WolfH , SchaferH , EhlersB , BreddinHK . Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin‐Study Group. International Angiology1998;17(3):135‐45. ">Kirchmaier 1998</a>; <a href="./references#CD001100-bbs2-0013" title="KoopmanMMW , PrandoniP , PiovellaF , OckelfordPA , BrandjesDPM , van denMeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low‐molecular‐weight heparin administered at home. New England Journal of Medicine1996;334(11):682‐7. ">Koopman 1996</a>; <a href="./references#CD001100-bbs2-0014" title="LeizoroviczA . Tinzaparin compared to unfractionated heparin for initial treatment of deep vein thrombosis in very elderly patients with renal insufficiency ‐ the IRIS trial. Blood2008; Vol. 112, issue 11:434. LeizoroviczA , SiguretV , MottierD . Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep((R)) in Renal Insufficiency Study (IRIS). Thrombosis Research2011;128(1):27‐34. NCT00277394 . Innohep© in elderly patients with impaired renal function treated for acute deep vein thrombosis. clinicaltrials.gov/ct/show/NCT002773942007. SiguretV , DeudonC , GolmardJ , LeizoroviczA , PautasE , Gouin‐ThibaultI . Pharmacodynamic response to unfractionated heparin used for initial treatment of acute deep vein thrombosis in elderly patients with renal impairment. A substudy of the IRIS clinical trial. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):805. ">Leizorovicz 2011</a>; <a href="./references#CD001100-bbs2-0015" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low‐molecular‐weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep‐vein thrombosis. New England Journal of Medicine1996;334(11):677‐81. ">Levine 1996</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>; <a href="./references#CD001100-bbs2-0019" title="MerliG , SpiroTE , OlssonCG , AbildgaardU , DavidsonBL , EldorA , et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191‐202. SpiroTE , The Enoxaparin Clinical Trial Group. A multicenter clinical trial comparing once and twice‐daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1997;374(Suppl):Abstract SC 1527. deLissovoyG , YusenRD , SpiroTE , KrupskiWC , ChampionAH , SorensenSV . Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Archives of Internal Medicine2000;160(20):3160‐5. ">Merli 2001</a>; <a href="./references#CD001100-bbs2-0020" title="MeyerG , BrenotF , PacouretG , SimonneauG , Gillet JuvinK , CharbonnierB , et al. Subcutaneous low‐molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thrombosis and Haemostasis1995;74(6):1432‐5. ">Meyer 1995</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>; <a href="./references#CD001100-bbs2-0025" title="PrandoniP , CarnovaliM , MarchioriA . Subcutaneous adjusted‐dose unfractionated heparin vs fixed‐dose low‐molecular‐weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164:1077‐83. ">Prandoni 2004</a>; <a href="./references#CD001100-bbs2-0026" title="RiessH , KoppenhagenK , TolleA , Kemkes‐MatthesB , GraveM , PatekF , et al. Fixed‐dose, body weight‐independent subcutaneous low molecular weight heparin Certoparin compared with adjusted‐dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thrombosis and Haemostasis2003;90(2):252‐9. RiessH , KoppenhagenK , TolleAR , Kemkes‐MatthesB , GraveM , HarenbergJ , et al. Fixed‐dose body weight‐independent subcutaneous LMW‐heparin (LMWH) certoparin is equally effective to adjusted‐dose intravenous uf‐heparin (UFH) for the initial treatment of proximal deep venous thrombosis (DVT). Annals of Hematology2001;80 Suppl 1:A56. ">Riess 2003</a>; <a href="./references#CD001100-bbs2-0027" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis. Archives of Internal Medicine1993;153(13):1541‐6. ">Simonneau 1993</a>; <a href="./references#CD001100-bbs2-0028" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJ‐P , AzarianR , et al. for the THESEE Study Group. A comparison of low‐molecular‐weight heparin with unfractionated heparin for acute pulmonary embolism. New England Journal of Medicine1997;337(10):663‐9. ">Simonneau 1997</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>). There was no difference in overall mortality at the end of follow‐up between participants treated with LMWH and UFH (Peto OR 0.84, 95% CI 0.70 to 1.01; moderate‐quality evidence; participants = 9663; studies = 24; P = 0.07). In the LMWH group, 234 (4.7%) of the 5004 participants died versus 265 (5.7%) of the 4659 participants in the UFH group. </p> <p>When analysed by LMWH preparation, certoparin was the only drug found to be associated with a reduction in overall mortality at the end of follow‐up (Peto OR 0.59, 95% CI 0.36 to 0.97; P = 0.04). Overall, no differences were observed between the heparin preparations in mortality at the end of follow‐up. </p> </section> <section id="CD001100-sec-0068"> <h4 class="title">Analysis in participants with proximal deep venous thrombosis (Analysis 2.1 to Analysis 2.6) </h4> <p>A total of 4878 participants with proximal deep venous thrombosis were enrolled in eleven studies (<a href="./references#CD001100-bbs2-0001" title="BelcaroG , NicolaidesAN , CesaroneMR , LauroraG , DeSanctisMT , IncandelaL , et al. Comparison of low‐molecular‐weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep‐vein thrombosis. Angiology1999;50(10):781‐7. ">Belcaro 1999</a>; <a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0010" title="HullRD , RaskobGE , BrantRF , PineoGF , ElliottG , SteinPD , et al. Low‐molecular‐weight heparin vs heparin in the treatment of patients with pulmonary embolism. American‐Canadian Thrombosis Study Group. Archives of Internal Medicine2000;160(2):229‐36. HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low‐molecular‐weight heparin compared with continuous intravenous heparin in the treatment of proximal‐vein thrombosis. New England Journal of Medicine1992;326(15):975‐82. ">Hull 1992</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0013" title="KoopmanMMW , PrandoniP , PiovellaF , OckelfordPA , BrandjesDPM , van denMeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low‐molecular‐weight heparin administered at home. New England Journal of Medicine1996;334(11):682‐7. ">Koopman 1996</a>; <a href="./references#CD001100-bbs2-0015" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low‐molecular‐weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep‐vein thrombosis. New England Journal of Medicine1996;334(11):677‐81. ">Levine 1996</a>; <a href="./references#CD001100-bbs2-0021" title="Moreno‐PalomaresJJ , Fisac‐HerreroRM , Herrero DomingoA , Ferreira‐PasosEM , GrasaJ , Reverte CejudoD . [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis]. Anales de Medicina Interna2001;18(7):364‐8. ">Moreno‐Palomares 2001</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>; <a href="./references#CD001100-bbs2-0026" title="RiessH , KoppenhagenK , TolleA , Kemkes‐MatthesB , GraveM , PatekF , et al. Fixed‐dose, body weight‐independent subcutaneous low molecular weight heparin Certoparin compared with adjusted‐dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thrombosis and Haemostasis2003;90(2):252‐9. RiessH , KoppenhagenK , TolleAR , Kemkes‐MatthesB , GraveM , HarenbergJ , et al. Fixed‐dose body weight‐independent subcutaneous LMW‐heparin (LMWH) certoparin is equally effective to adjusted‐dose intravenous uf‐heparin (UFH) for the initial treatment of proximal deep venous thrombosis (DVT). Annals of Hematology2001;80 Suppl 1:A56. ">Riess 2003</a>; <a href="./references#CD001100-bbs2-0027" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis. Archives of Internal Medicine1993;153(13):1541‐6. ">Simonneau 1993</a>). Seven preparations of LMWH were used: nadroparin (three trials, 864 participants), dalteparin (one trial, 30 participants), tinzaparin (one trial, 432 participants), enoxaparin (two trials, 634 participants), reviparin (one trial, 763 participants), certoparin (two trials, 1758 participants) and bemiparin (one trial, 397 participants). In the three‐armed trial by <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a> two bemiparin groups were compared with an UFH control group. However, in one of the bemiparin groups, participants did not receive concomitant VKA therapy. All other studies included in this review used concomitant VKA therapy and in order for our results to be comparable, data for this group of participants in the <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a> study was not included in the analysis. </p> <p>At the end of follow‐up, 80 (3.5%) of the 2303 participants treated with LMWH had a symptomatic recurrent venous thromboembolic event versus 143 (6.0%) of the 2369 participants treated with UFH. This reduction was in favour of LMWH (Peto OR 0.57, 95% CI 0.44 to 0.75; participants = 4672; studies = 10; P &lt; 0.0001) (<a href="./references#CD001100-fig-0014" title="">Analysis 2.1</a>). When analysed by LMWH preparation, reviparin was the only drug associated with a reduction in recurrent VTE (Peto OR 0.31, 95% CI 0.15 to 0.63). Overall, no differences were observed between the heparin preparations in symptomatic recurrent venous thromboembolism at the end of follow‐up. </p> <p>LMWH was also associated with a reduction in the incidence of symptomatic, recurrent deep venous thrombosis as well as a reduction in the incidence of pulmonary embolism (respectively Peto OR 0.61, 95% CI 0.41 to 0.91; participants = 2681; studies = 7; P = 0.02; and Peto OR 0.45, 95% CI 0.28 to 0.74; participants = 3024; studies = 7; P = 0.002) (<a href="./references#CD001100-fig-0015" title="">Analysis 2.2</a>; <a href="./references#CD001100-fig-0016" title="">Analysis 2.3</a>). When analysed by type of LMWH preparation, reviparin and certoparin were the only drugs associated with a reduction in the incidence of pulmonary embolism (respectively Peto OR 0.27, 95% CI 0.10 to 0.73; and Peto OR 0.32, 95% CI 0.11 to 0.92). Overall, no differences were observed between the heparin preparations in symptomatic recurrent deep venous thrombosis and pulmonary embolism at the end of follow‐up. </p> <p>Pooled analysis of two studies demonstrated a reduction of thrombus size in 73% of the participants treated with LMWH and in 56% of participants treated with UFH (<a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0021" title="Moreno‐PalomaresJJ , Fisac‐HerreroRM , Herrero DomingoA , Ferreira‐PasosEM , GrasaJ , Reverte CejudoD . [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis]. Anales de Medicina Interna2001;18(7):364‐8. ">Moreno‐Palomares 2001</a>). LMWH was associated with a better venographic outcome — Peto OR 0.47, 95% CI 0.27 to 0.80; participants = 230; studies = 2; P = 0.006 (<a href="./references#CD001100-fig-0017" title="">Analysis 2.4</a>) — with the result heavily influenced by the <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a> study on bemiparin showing a reduction in thrombus size with LMWH (Peto OR 0.42, 95% CI 0.24 to 0.74; participants = 203; studies = 1; P = 0.003) compared with UFH. </p> <p>Analysis of the pooled data showed a reduction in major haemorrhagic complications in favour of LMWH (Peto OR 0.50, 95% CI 0.29 to 0.85; participants = 3589; studies = 8; P = 0.01) (<a href="./references#CD001100-fig-0018" title="">Analysis 2.5</a>). At the end of the initial treatment period, 18 (1.0%) of the 1804 participants in the LMWH group versus 37 (2.1%) of the 1785 participants in the UFH group suffered a major haemorrhage. Tinzaparin was the only LMWH preparation associated with reduced rates of major haemorrhagic complications (Peto OR 0.19, 95% CI 0.06 to 0.59). Overall, no differences were observed between the heparin preparations in incidence of major haemorrhages during initial treatment. </p> <p>Overall mortality at the end of follow‐up demonstrated a reduction in favour of LMWH (Peto OR 0.63, 95% CI 0.47 to 0.85; participants = 4331; studies = 9; P = 0.002) (<a href="./references#CD001100-fig-0019" title="">Analysis 2.6</a>). In the LMWH group, 72 (3.3%) of the 2183 participants died versus 112 (5.2%) of the 2148 participants in the UFH group. Certorparin was the only LMWH preparation associated with a reduction in overall mortality (Peto OR 0.54, 95% CI 0.30 to 0.96). Overall, no differences were observed between the heparin preparations in overall mortality at the end of follow‐up. </p> </section> <section id="CD001100-sec-0069"> <h4 class="title">Analysis in participants with pulmonary embolism (Analysis 3.1)</h4> <p>A total of 1407 participants with pulmonary embolism were enrolled in seven studies (<a href="./references#CD001100-bbs2-0003" title="DouketisJD , FosterGA , CrowtherMA , PrinsMH , GinsbergJS . Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine2000;160(22):3431‐6. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep‐vein thrombosis and pulmonary embolism. Blood1996; Vol. 88:626a. The Columbus Investigators. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657‐62. tenCateJW , BüllerHR , GentM , GallusAS , GinsbergJ , PrinsMH , et al. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. Journal of Vascular and Interventional Radiology1998;9:178. ">Columbus 1997</a>; <a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0019" title="MerliG , SpiroTE , OlssonCG , AbildgaardU , DavidsonBL , EldorA , et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191‐202. SpiroTE , The Enoxaparin Clinical Trial Group. A multicenter clinical trial comparing once and twice‐daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1997;374(Suppl):Abstract SC 1527. deLissovoyG , YusenRD , SpiroTE , KrupskiWC , ChampionAH , SorensenSV . Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Archives of Internal Medicine2000;160(20):3160‐5. ">Merli 2001</a>; <a href="./references#CD001100-bbs2-0020" title="MeyerG , BrenotF , PacouretG , SimonneauG , Gillet JuvinK , CharbonnierB , et al. Subcutaneous low‐molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thrombosis and Haemostasis1995;74(6):1432‐5. ">Meyer 1995</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>; <a href="./references#CD001100-bbs2-0028" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJ‐P , AzarianR , et al. for the THESEE Study Group. A comparison of low‐molecular‐weight heparin with unfractionated heparin for acute pulmonary embolism. New England Journal of Medicine1997;337(10):663‐9. ">Simonneau 1997</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>). Four preparations of LMWH were used: tinzaparin (one trial, 612 participants), enoxaparin (three trials, 396 participants), dalteparin (two trials, 128 participants), and reviparin (one trial, 271 participants). In the study by <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>, two other treatment groups were given a high dose of nadroparin (600 and 900 anti‐factor Xa IU/kg). Data from these groups were not included in the analysis in this review. </p> <p>All seven studies measured the rate of recurrent thromboembolic events at the end of follow‐up. Analysis of pooled data showed no difference between participants treated with LMWH and UFH (Peto OR 0.90, 95% CI 0.50 to 1.61; participants = 1407; studies = 7; P = 0.73) (<a href="./references#CD001100-fig-0020" title="">Analysis 3.1</a>). No individual LMWH preparation was associated with a reduction in the rate of recurrent VTE. </p> <p>Two studies measured change in thrombus size (<a href="./references#CD001100-bbs2-0020" title="MeyerG , BrenotF , PacouretG , SimonneauG , Gillet JuvinK , CharbonnierB , et al. Subcutaneous low‐molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thrombosis and Haemostasis1995;74(6):1432‐5. ">Meyer 1995</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>). Pooled analysis showed no difference in the number of LMWH and UFH participants whose thrombus size improved (Peto OR 1.36, 95% CI 0.23 to 8.16; participants = 106; studies = 2; P = 0.74) (<a href="./references#CD001100-fig-0021" title="">Analysis 3.2</a>). Both studies also measured change in thrombus size according to improvement in the Miller (<a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>) or peripheral vascular obstruction score (PVOS) (<a href="./references#CD001100-bbs2-0020" title="MeyerG , BrenotF , PacouretG , SimonneauG , Gillet JuvinK , CharbonnierB , et al. Subcutaneous low‐molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thrombosis and Haemostasis1995;74(6):1432‐5. ">Meyer 1995</a>). Pooled analysis showed an improvement (MD −3.14, 95% CI −4.39 to −1.90; participants = 106; studies = 2; P &lt; 0.00001) (<a href="./references#CD001100-fig-0022" title="">Analysis 3.3</a>). No individual LMWH preparation was associated with a change in thrombus size. </p> <p>Three studies measured the incidence of major haemorrhagic complications during initial treatment or within 48 hours after treatment cessation (<a href="./references#CD001100-bbs2-0020" title="MeyerG , BrenotF , PacouretG , SimonneauG , Gillet JuvinK , CharbonnierB , et al. Subcutaneous low‐molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thrombosis and Haemostasis1995;74(6):1432‐5. ">Meyer 1995</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>). Pooled analysis showed no difference in the incidence of major bleeding between the LMWH and UFH groups (Peto OR 0.44, 95% CI 0.04 to 4.29; participants = 178; studies = 3; P = 0.48) (<a href="./references#CD001100-fig-0023" title="">Analysis 3.4</a>). However there was significant heterogeneity in this analysis (I² = 58%). No individual LMWH preparation was associated with a reduction in the rate of major haemorrhagic complications. </p> <p>Three studies measured overall mortality (<a href="./references#CD001100-bbs2-0020" title="MeyerG , BrenotF , PacouretG , SimonneauG , Gillet JuvinK , CharbonnierB , et al. Subcutaneous low‐molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thrombosis and Haemostasis1995;74(6):1432‐5. ">Meyer 1995</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>). We found no difference in the overall mortality incidence between the LMWH and UFH groups (Peto OR 1.70, 95% CI 0.17 to 16.71; participants = 178; studies = 3; P = 0.65) (<a href="./references#CD001100-fig-0024" title="">Analysis 3.5</a>). No individual LMWH preparation was associated with reduced overall mortality. </p> </section> <section id="CD001100-sec-0070"> <h4 class="title">Analysis in participants with venous thromboembolism with or without malignant disease (Analysis 4.1 to Analysis 5.1) </h4> <p>Six studies evaluated mortality at the end of follow‐up in participants with and without malignant disease (<a href="./references#CD001100-bbs2-0003" title="DouketisJD , FosterGA , CrowtherMA , PrinsMH , GinsbergJS . Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine2000;160(22):3431‐6. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep‐vein thrombosis and pulmonary embolism. Blood1996; Vol. 88:626a. The Columbus Investigators. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657‐62. tenCateJW , BüllerHR , GentM , GallusAS , GinsbergJ , PrinsMH , et al. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. Journal of Vascular and Interventional Radiology1998;9:178. ">Columbus 1997</a>; <a href="./references#CD001100-bbs2-0010" title="HullRD , RaskobGE , BrantRF , PineoGF , ElliottG , SteinPD , et al. Low‐molecular‐weight heparin vs heparin in the treatment of patients with pulmonary embolism. American‐Canadian Thrombosis Study Group. Archives of Internal Medicine2000;160(2):229‐36. HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low‐molecular‐weight heparin compared with continuous intravenous heparin in the treatment of proximal‐vein thrombosis. New England Journal of Medicine1992;326(15):975‐82. ">Hull 1992</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>; <a href="./references#CD001100-bbs2-0028" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJ‐P , AzarianR , et al. for the THESEE Study Group. A comparison of low‐molecular‐weight heparin with unfractionated heparin for acute pulmonary embolism. New England Journal of Medicine1997;337(10):663‐9. ">Simonneau 1997</a>). One of these studies individually showed a reduction in deaths at the end of follow‐up with LMWH (Peto OR 0.16, 95% CI 0.03 to 0.72; P = 0.02) (<a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>). Combining the six studies also demonstrated a reduction in overall mortality in participants with cancer who were treated with LMWH (Peto OR 0.53, 95% CI 0.33 to 0.85; participants = 446; P = 0.009) (<a href="./references#CD001100-fig-0025" title="">Analysis 4.1</a>). In participants without cancer who received LMWH, the reduction in overall mortality of approximately 1% was not different between LMWH and UFH (Peto OR 0.97, 95% CI 0.61 to 1.56; participants = 2139; P = 0.91) (<a href="./references#CD001100-fig-0026" title="">Analysis 5.1</a>). </p> <p>Data on recurrent VTE, reduction in thrombus size and major haemorrhage during initial treatment were not available for the group of participants with or without malignant disease. </p> </section> <section id="CD001100-sec-0071"> <h4 class="title">Analysis of studies of subcutaneous UFH versus LMWH (Analysis 6.1; Analysis 6.2; Analysis 6.3) </h4> <p>In four studies the UFH in the control group was administered subcutaneously although they did not all report on all outcomes (<a href="./references#CD001100-bbs2-0005" title="FaivreR , NeuhartE , KiefferY , ToulemondeF , BassandJP , MauratJP . Subcutaneous administration of a low molecular weight heparin (CY 222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis. Thrombosis and Haemostasis1987;58(1):Abstract 430. FaivreR , NeuhartY , KiefferY , ApfelF , MagninD , DidierD , et al. A new treatment of deep vein thrombosis: low molecular weight heparin fractions. Randomised study [Un nouveau traitement des thromboses veineuses profondes: les fractions d'heparine de bas poids moleculaire. Etude randomisee]. Presse Medicale1988;17(5):197‐200. ">Faivre 1988</a>; <a href="./references#CD001100-bbs2-0014" title="LeizoroviczA . Tinzaparin compared to unfractionated heparin for initial treatment of deep vein thrombosis in very elderly patients with renal insufficiency ‐ the IRIS trial. Blood2008; Vol. 112, issue 11:434. LeizoroviczA , SiguretV , MottierD . Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep((R)) in Renal Insufficiency Study (IRIS). Thrombosis Research2011;128(1):27‐34. NCT00277394 . Innohep© in elderly patients with impaired renal function treated for acute deep vein thrombosis. clinicaltrials.gov/ct/show/NCT002773942007. SiguretV , DeudonC , GolmardJ , LeizoroviczA , PautasE , Gouin‐ThibaultI . Pharmacodynamic response to unfractionated heparin used for initial treatment of acute deep vein thrombosis in elderly patients with renal impairment. A substudy of the IRIS clinical trial. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):805. ">Leizorovicz 2011</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0025" title="PrandoniP , CarnovaliM , MarchioriA . Subcutaneous adjusted‐dose unfractionated heparin vs fixed‐dose low‐molecular‐weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164:1077‐83. ">Prandoni 2004</a>). The analysis of the pooled data from these studies demonstrated no reduction in recurrent venous thromboembolism at the end of follow‐up (Peto OR 1.05, 95% CI 0.56 to 1.95; participants = 1403; studies = 3; P = 0.88). However there was significant heterogeneity (I² = 58%). There was no difference in the incidence of major haemorrhagic complications (Peto OR 0.91, 95% CI 0.50 to 1.67; participants = 1471; studies = 4; P = 0.76), nor overall mortality (Peto OR 1.46, 95% CI 0.91 to 2.35; participants = 1403; studies = 3; P = 0.12), between groups treated with subcutaneous UFH and LMWH. </p> <p>Data on reduction in thrombus size were not available for the group of participants who received subcutaneous UFH versus LMWH. </p> </section> <section id="CD001100-sec-0072"> <h4 class="title">Analysis of studies of intravenous UFH versus LMWH (Analysis 7.1; Analysis 7.2; Analysis 7.3) </h4> <p>In the 21 studies which compared LMWH with intravenous UFH we found a reduction in recurrent venous thromboembolism at the end of follow‐up (Peto OR 0.69, 95% CI 0.56 to 0.86; participants = 8375; studies = 21; P = 0.0007); in major haemorrhages (Peto OR 0.62, 95% CI 0.43 to 0.90; participants = 7309; studies = 21; P = 0.01); and in overall mortality (Peto OR 0.77, 95% CI 0.63 to 0.93; participants = 8260; studies = 21; P = 0.008) (<a href="./references#CD001100-bbs2-0001" title="BelcaroG , NicolaidesAN , CesaroneMR , LauroraG , DeSanctisMT , IncandelaL , et al. Comparison of low‐molecular‐weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep‐vein thrombosis. Angiology1999;50(10):781‐7. ">Belcaro 1999</a>; <a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>; <a href="./references#CD001100-bbs2-0003" title="DouketisJD , FosterGA , CrowtherMA , PrinsMH , GinsbergJS . Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine2000;160(22):3431‐6. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep‐vein thrombosis and pulmonary embolism. Blood1996; Vol. 88:626a. The Columbus Investigators. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657‐62. tenCateJW , BüllerHR , GentM , GallusAS , GinsbergJ , PrinsMH , et al. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. Journal of Vascular and Interventional Radiology1998;9:178. ">Columbus 1997</a>; <a href="./references#CD001100-bbs2-0004" title="DecoususH , LeizoroviczA , ParentF , PageY , TardyB , GirardPH , et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep‐vein thrombosis. New England Journal of Medicine1998;338(7):409‐15. ">Decousus 1998</a>; <a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0008" title="GoldhaberSZ , MorrisonRB , DiranLL , CreagerMA , LeeTHJr . Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Archives of Internal Medicine1998;158(21):2325‐8. ">Goldhaber 1998</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0010" title="HullRD , RaskobGE , BrantRF , PineoGF , ElliottG , SteinPD , et al. Low‐molecular‐weight heparin vs heparin in the treatment of patients with pulmonary embolism. American‐Canadian Thrombosis Study Group. Archives of Internal Medicine2000;160(2):229‐36. HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low‐molecular‐weight heparin compared with continuous intravenous heparin in the treatment of proximal‐vein thrombosis. New England Journal of Medicine1992;326(15):975‐82. ">Hull 1992</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0012" title="KirchmaierCM , WolfH , SchaferH , EhlersB , BreddinHK . Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin‐Study Group. International Angiology1998;17(3):135‐45. ">Kirchmaier 1998</a>; <a href="./references#CD001100-bbs2-0013" title="KoopmanMMW , PrandoniP , PiovellaF , OckelfordPA , BrandjesDPM , van denMeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low‐molecular‐weight heparin administered at home. New England Journal of Medicine1996;334(11):682‐7. ">Koopman 1996</a>; <a href="./references#CD001100-bbs2-0015" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low‐molecular‐weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep‐vein thrombosis. New England Journal of Medicine1996;334(11):677‐81. ">Levine 1996</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0019" title="MerliG , SpiroTE , OlssonCG , AbildgaardU , DavidsonBL , EldorA , et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191‐202. SpiroTE , The Enoxaparin Clinical Trial Group. A multicenter clinical trial comparing once and twice‐daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1997;374(Suppl):Abstract SC 1527. deLissovoyG , YusenRD , SpiroTE , KrupskiWC , ChampionAH , SorensenSV . Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Archives of Internal Medicine2000;160(20):3160‐5. ">Merli 2001</a>; <a href="./references#CD001100-bbs2-0020" title="MeyerG , BrenotF , PacouretG , SimonneauG , Gillet JuvinK , CharbonnierB , et al. Subcutaneous low‐molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thrombosis and Haemostasis1995;74(6):1432‐5. ">Meyer 1995</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>; <a href="./references#CD001100-bbs2-0026" title="RiessH , KoppenhagenK , TolleA , Kemkes‐MatthesB , GraveM , PatekF , et al. Fixed‐dose, body weight‐independent subcutaneous low molecular weight heparin Certoparin compared with adjusted‐dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thrombosis and Haemostasis2003;90(2):252‐9. RiessH , KoppenhagenK , TolleAR , Kemkes‐MatthesB , GraveM , HarenbergJ , et al. Fixed‐dose body weight‐independent subcutaneous LMW‐heparin (LMWH) certoparin is equally effective to adjusted‐dose intravenous uf‐heparin (UFH) for the initial treatment of proximal deep venous thrombosis (DVT). Annals of Hematology2001;80 Suppl 1:A56. ">Riess 2003</a>; <a href="./references#CD001100-bbs2-0027" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis. Archives of Internal Medicine1993;153(13):1541‐6. ">Simonneau 1993</a>; <a href="./references#CD001100-bbs2-0028" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJ‐P , AzarianR , et al. for the THESEE Study Group. A comparison of low‐molecular‐weight heparin with unfractionated heparin for acute pulmonary embolism. New England Journal of Medicine1997;337(10):663‐9. ">Simonneau 1997</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>). </p> <p>Data on reduction in thrombus size were not available for the group of participants who received intravenous UFH versus LMWH. </p> </section> <section id="CD001100-sec-0073"> <h4 class="title">Sensitivity analysis of studies with adequate concealment of allocation prior to randomisation (Analysis 8.1 to Analysis 8.6) </h4> <p>Fourteen studies had clear concealment of allocation prior to randomisation based on the information given in the publications (<a href="./references#CD001100-bbs2-0003" title="DouketisJD , FosterGA , CrowtherMA , PrinsMH , GinsbergJS . Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine2000;160(22):3431‐6. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep‐vein thrombosis and pulmonary embolism. Blood1996; Vol. 88:626a. The Columbus Investigators. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657‐62. tenCateJW , BüllerHR , GentM , GallusAS , GinsbergJ , PrinsMH , et al. Low‐molecular‐weight heparin in the treatment of patients with venous thromboembolism. Journal of Vascular and Interventional Radiology1998;9:178. ">Columbus 1997</a>; <a href="./references#CD001100-bbs2-0004" title="DecoususH , LeizoroviczA , ParentF , PageY , TardyB , GirardPH , et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep‐vein thrombosis. New England Journal of Medicine1998;338(7):409‐15. ">Decousus 1998</a>; <a href="./references#CD001100-bbs2-0008" title="GoldhaberSZ , MorrisonRB , DiranLL , CreagerMA , LeeTHJr . Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Archives of Internal Medicine1998;158(21):2325‐8. ">Goldhaber 1998</a>; <a href="./references#CD001100-bbs2-0010" title="HullRD , RaskobGE , BrantRF , PineoGF , ElliottG , SteinPD , et al. Low‐molecular‐weight heparin vs heparin in the treatment of patients with pulmonary embolism. American‐Canadian Thrombosis Study Group. Archives of Internal Medicine2000;160(2):229‐36. HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low‐molecular‐weight heparin compared with continuous intravenous heparin in the treatment of proximal‐vein thrombosis. New England Journal of Medicine1992;326(15):975‐82. ">Hull 1992</a>; <a href="./references#CD001100-bbs2-0012" title="KirchmaierCM , WolfH , SchaferH , EhlersB , BreddinHK . Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin‐Study Group. International Angiology1998;17(3):135‐45. ">Kirchmaier 1998</a>; <a href="./references#CD001100-bbs2-0013" title="KoopmanMMW , PrandoniP , PiovellaF , OckelfordPA , BrandjesDPM , van denMeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low‐molecular‐weight heparin administered at home. New England Journal of Medicine1996;334(11):682‐7. ">Koopman 1996</a>; <a href="./references#CD001100-bbs2-0015" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low‐molecular‐weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep‐vein thrombosis. New England Journal of Medicine1996;334(11):677‐81. ">Levine 1996</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0019" title="MerliG , SpiroTE , OlssonCG , AbildgaardU , DavidsonBL , EldorA , et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191‐202. SpiroTE , The Enoxaparin Clinical Trial Group. A multicenter clinical trial comparing once and twice‐daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1997;374(Suppl):Abstract SC 1527. deLissovoyG , YusenRD , SpiroTE , KrupskiWC , ChampionAH , SorensenSV . Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Archives of Internal Medicine2000;160(20):3160‐5. ">Merli 2001</a>; <a href="./references#CD001100-bbs2-0024" title="PrandoniP , LensingAWA , BüllerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low‐molecular‐weight heparin with intravenous standard heparin in proximal deep‐vein thrombosis. Lancet1992;339(8791):441‐5. ">Prandoni 1992</a>; <a href="./references#CD001100-bbs2-0025" title="PrandoniP , CarnovaliM , MarchioriA . Subcutaneous adjusted‐dose unfractionated heparin vs fixed‐dose low‐molecular‐weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164:1077‐83. ">Prandoni 2004</a>; <a href="./references#CD001100-bbs2-0026" title="RiessH , KoppenhagenK , TolleA , Kemkes‐MatthesB , GraveM , PatekF , et al. Fixed‐dose, body weight‐independent subcutaneous low molecular weight heparin Certoparin compared with adjusted‐dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thrombosis and Haemostasis2003;90(2):252‐9. RiessH , KoppenhagenK , TolleAR , Kemkes‐MatthesB , GraveM , HarenbergJ , et al. Fixed‐dose body weight‐independent subcutaneous LMW‐heparin (LMWH) certoparin is equally effective to adjusted‐dose intravenous uf‐heparin (UFH) for the initial treatment of proximal deep venous thrombosis (DVT). Annals of Hematology2001;80 Suppl 1:A56. ">Riess 2003</a>; <a href="./references#CD001100-bbs2-0027" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis. Archives of Internal Medicine1993;153(13):1541‐6. ">Simonneau 1993</a>; <a href="./references#CD001100-bbs2-0028" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJ‐P , AzarianR , et al. for the THESEE Study Group. A comparison of low‐molecular‐weight heparin with unfractionated heparin for acute pulmonary embolism. New England Journal of Medicine1997;337(10):663‐9. ">Simonneau 1997</a>). The analysis of the pooled data from these studies demonstrated no difference between LMWH and UFH in recurrent venous thromboembolism during the initial treatment period (Peto OR 0.72, 95% CI 0.50 to 1.05; participants = 4862; studies = 10; P = 0.09) nor at three months (Peto OR 0.79, 95% CI 0.60 to 1.02; participants = 5435; studies = 11; P = 0.07). However, LMWH was associated with both a reduction in the incidence of recurrent VTE at the end of follow‐up (Peto OR 0.76, 95% CI 0.60 to 0.96; participants = 6984; studies = 14; P = 0.02) and overall mortality (Peto OR 0.80, 95% CI 0.65 to 0.99; participants = 6984; studies = 14; P = 0.04). Major haemorrhage (Peto OR 0.68, 95% CI 0.45 to 1.03; participants = 6014; studies = 12; P = 0.07) was not different after treatment with LMWH compared with UFH. The reduction in the thrombus size, however, was in favour of LMWH (Peto OR 0.49, 95% CI 0.37 to 0.66; participants = 753; studies = 5; P &lt; 0.00001). Therefore, while reductions in recurrent venous thromboembolism, major haemorrhages and overall mortality were observed in the LMWH group compared with UFH when all studies were combined, in a sensitivity analysis of studies with adequate concealment of treatment allocation before randomisation, no differences were observed in the incidence of recurrent venous thromboembolism during initial treatment and after three months nor in the incidence of major haemorrhages between LMWH and UFH. </p> </section> <section id="CD001100-sec-0074"> <h4 class="title">Sensitivity analysis of studies that used the International Society on Thrombosis and Haemostasis (ISTH) definition of major and clinically relevant bleeding (Analysis 9.1) </h4> <p>Only one study did not use the ISTH definition of major bleeding and was excluded for the sensitivity analysis (<a href="./references#CD001100-bbs2-0005" title="FaivreR , NeuhartE , KiefferY , ToulemondeF , BassandJP , MauratJP . Subcutaneous administration of a low molecular weight heparin (CY 222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis. Thrombosis and Haemostasis1987;58(1):Abstract 430. FaivreR , NeuhartY , KiefferY , ApfelF , MagninD , DidierD , et al. A new treatment of deep vein thrombosis: low molecular weight heparin fractions. Randomised study [Un nouveau traitement des thromboses veineuses profondes: les fractions d'heparine de bas poids moleculaire. Etude randomisee]. Presse Medicale1988;17(5):197‐200. ">Faivre 1988)</a>. Analysis of the pooled data showed a reduction in major haemorrhagic complications in favour of LMWH (Peto OR 0.71, 95% CI 0.52 to 0.98; participants = 8712; studies = 24; P = 0.04). These results are similar to the results from the analysis including all studies irrespective of their definition of major and clinically relevant bleeding (<a href="./references#CD001100-fig-0012" title="">Analysis 1.7</a>). </p> </section> <section id="CD001100-sec-0075"> <h4 class="title">Trends over time (Analysis 10.1 to Analysis 10.4)</h4> <p>In order to investigate the trend over time, we performed analyses in which all studies were ordered by their date of publication. The forest plots of these analyses did not show an obvious trend over time. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001100-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001100-sec-0076"></div> <section id="CD001100-sec-0077"> <h3 class="title" id="CD001100-sec-0077">Summary of main results</h3> <p>Our review of low molecular weight heparin (LMWH) for the initial treatment of venous thromboembolism (VTE) includes more than 9000 participants and indicates that this drug may be more efficacious than unfractionated heparin (UFH) for preventing recurrent VTE. Many of the included studies reported on other advantages of LMWH over UFH. Firstly, the route of administration (subcutaneous once or twice daily) is more convenient and increases the mobility of participants with VTE. Secondly, the pharmacokinetics are more predictable, which abolishes the need for laboratory monitoring and subsequent dose adjustments. Hence, LMWH can be advocated as the standard therapy for people with confirmed VTE. Treatment in an outpatient setting has been demonstrated to be feasible, safe and cost‐effective for people with DVT (<a href="./references#CD001100-bbs2-0013" title="KoopmanMMW , PrandoniP , PiovellaF , OckelfordPA , BrandjesDPM , van denMeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low‐molecular‐weight heparin administered at home. New England Journal of Medicine1996;334(11):682‐7. ">Koopman 1996</a>; <a href="./references#CD001100-bbs2-0015" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low‐molecular‐weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep‐vein thrombosis. New England Journal of Medicine1996;334(11):677‐81. ">Levine 1996</a>; <a href="./references#CD001100-bbs2-0076" title="van denBeltAGM , BossuytPMM , PrinsMH , GallusAS , BullerHR , KoopmanMMW , et al. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis. An economic evaluation. Thrombosis and Haemostasis1998;79(2):259‐63. ">van den Belt 1998</a>). </p> <p>Analysis of all studies, regardless of methodological quality, showed that LMWH was associated with a lower incidence of recurrent VTE at the end of follow‐up and at three and six months, with 95% CIs less than one (Peto OR 0.72, 95% CI 0.59 to 0.88, Peto OR 0.71, 95% CI 0.56 to 0.90 and Peto OR 0.68, 95% CI 0.48 to 0.96 respectively) but not after one month follow‐up (Peto OR 0.90, 95% CI 0.56 to 1.44). However, when sensitivity analysis was performed on studies that concealed allocation of treatment only, no differences were observed in the incidence of recurrent venous thromboembolism during initial treatment and after three months nor in the incidence of major haemorrhages between LMWH and UFH. We therefore judge that the quality of the evidence is moderate. </p> <p>When we performed analyses according to the type of VTE index event, the rate of recurrent VTE at the end of follow‐up remained lower in DVT participants treated with LMWH compared with DVT participants treated with UFH (Peto OR 0.57, 95% CI 0.44 to 0.75). However, analysis in participants with PE showed no difference in the rate of recurrent VTE between the two treatment groups (Peto OR 0.90, 95% CI 0.50 to 1.61). When we performed analyses according to mode of delivery of UFH, we found that LMWH was associated with fewer recurrent VTEs than intravenous UFH (Peto OR 0.69, 95% CI 0.56 to 0.86) but that there was no difference when LMWH was compared with subcutaneous UFH (Peto OR 1.05, 95% CI 0.56 to 1.95). </p> <p>The tendency to improved efficacy with LMWH treatment was not at the cost of a higher rate of major haemorrhage. On the contrary, a reduction in major haemorrhage was demonstrated during the initial treatment period with LMWH. This is largely because the LMWH provides a more stable level of anticoagulation whereas unfractionated heparin dose adjustments may result in more peaks and troughs of anticoagulant effect. </p> </section> <section id="CD001100-sec-0078"> <h3 class="title" id="CD001100-sec-0078">Overall completeness and applicability of evidence</h3> <p>Although these results are promising, there are a number of unresolved issues. Firstly, since only approximately 25% of the participants included in this critical review had a diagnosis of primary pulmonary embolism, it can be argued that more data are required before conclusions can be drawn in this population. Secondly, although the combination of all preparations of LMWH seems logical, and heterogeneity could not be identified, current data do not discriminate between different LMWH preparations. A difference between LMWH preparations was only found for one outcome of the review, reduction in thrombus size. However, studies with large sample sizes and which include comparisons of different preparations are needed to determine whether the efficacy and safety of the individual LMWHs is actually comparable. Thirdly, Prandoni and colleagues noted that the route of administration might be relevant to heparin efficacy (<a href="./references#CD001100-bbs2-0025" title="PrandoniP , CarnovaliM , MarchioriA . Subcutaneous adjusted‐dose unfractionated heparin vs fixed‐dose low‐molecular‐weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164:1077‐83. ">Prandoni 2004</a>). When we limited the analysis to studies that used intravenous UFK, similar results as in the main analyses were observed. When the analysis was confined to those studies that used subcutaneous UFH we found no difference in the incidence of recurrent VTE and major haemorrhages. The lack of difference could be due to the smaller groups in this analysis. </p> <p>The protocol for this review was published in 1997 and the first version of the review was published in 1998. Initial treatment of VTE has changed since then and, as a result, the current objective of this review is no longer as clinically relevant as before. Therefore, to reflect current practice, future updates of this review will include studies on fixed dose subcutaneous UFH. Additionally, in accordance with current VTE trials on direct‐acting oral anticoagulants, future updates will assess symptomatic PE and symptomatic proximal DVT as the primary outcome. We will also assess side effects of treatment other than bleeding as an additional outcome. </p> </section> <section id="CD001100-sec-0079"> <h3 class="title" id="CD001100-sec-0079">Quality of the evidence</h3> <p>The quality of the evidence was downgraded to moderate due to concerns arising from risk of bias in individual studies. One study was at risk of selection bias (<a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>), six studies were at risk of attrition bias (<a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>; <a href="./references#CD001100-bbs2-0006" title="FiessingerJN , FernandezML , GattererE , OhlssonCG . Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial. Haemostasis1994;24(Suppl 1):Abstract 44. FiessingerJN , Lopez‐FernandezM , GattererE , GranqvistS , KherA , OlssonCG , et al. Once‐daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1996;76(2):195‐9. ">Fiessinger 1996</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0022" title="NinetJ , BachetP , PrandoniP , RuolA , VigoM , BarretA , et al. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1991;65(3):251‐6. ">Ninet 1991</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>), two studies were at risk of reporting bias (<a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>), and three studies were at risk for other types of bias including baseline differences between the groups (<a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>). A further reason for downgrading the evidence to moderate was that several studies did not adequately report on the methods used to generate the random sequence nor how treatment allocation was kept concealed. </p> <p>While reductions in recurrent VTE and major haemorrhages were observed in the LMWH group compared with UFH when all studies were combined, in a sensitivity analysis of studies with adequate concealment of treatment allocation before randomisation, no differences were observed in the incidence of recurrent VTE during initial treatment and after three months nor in the incidence of major haemorrhages between LMWH and UFH. An explanation for these differences in effect size could be that the overall reductions are possibly biased by including less adequately performed studies without adequate concealment. </p> <p>Where there were 10 or more studies in an analysis, we tested for publication bias using funnel plots. We found a suggestion of publication bias for three of the outcomes: incidence of recurrent VTE during initial treatment (<a href="./references#CD001100-fig-0006" title="">Analysis 1.1,</a><a href="#CD001100-fig-0003">Figure 3</a>);incidence of recurrent VTE at three months (<a href="./references#CD001100-fig-0009" title="">Analysis 1.4</a>, <a href="#CD001100-fig-0004">Figure 4</a>); and reduction in thrombus size (<a href="./references#CD001100-fig-0011" title="">Analysis 1.6</a>, <a href="#CD001100-fig-0005">Figure 5</a>). However, we felt it was insufficient to downgrade for publication bias. For the remaining outcomes, we found no evidence of publication bias for the analyses we tested (<a href="./references#CD001100-fig-0007" title="">Analysis 1.2</a>; <a href="./references#CD001100-fig-0012" title="">Analysis 1.7</a>; <a href="./references#CD001100-fig-0013" title="">Analysis 1.8</a>; <a href="./references#CD001100-fig-0014" title="">Analysis 2.1</a>; <a href="./references#CD001100-fig-0030" title="">Analysis 7.1</a>; <a href="./references#CD001100-fig-0031" title="">Analysis 7.2</a>; <a href="./references#CD001100-fig-0032" title="">Analysis 7.3</a>; <a href="./references#CD001100-fig-0033" title="">Analysis 8.1</a>; <a href="./references#CD001100-fig-0034" title="">Analysis 8.2</a>; <a href="./references#CD001100-fig-0035" title="">Analysis 8.3</a>; <a href="./references#CD001100-fig-0037" title="">Analysis 8.5</a>; <a href="./references#CD001100-fig-0038" title="">Analysis 8.6</a>; <a href="./references#CD001100-fig-0040" title="">Analysis 10.1</a>; <a href="./references#CD001100-fig-0041" title="">Analysis 10.2</a>; <a href="./references#CD001100-fig-0042" title="">Analysis 10.3</a>; <a href="./references#CD001100-fig-0043" title="">Analysis 10.4</a>). </p> <div class="figure" id="CD001100-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 LMWH versus UFH in people with venous thromboembolism, outcome: 1.1 Incidence of recurrent venous thromboembolism during initial treatment." data-id="CD001100-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 LMWH versus UFH in people with venous thromboembolism, outcome: 1.1 Incidence of recurrent venous thromboembolism during initial treatment. </p> </div> </div> </div> <div class="figure" id="CD001100-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 LMWH versus UFH in people with venous thromboembolism, outcome: 1.4 Incidence of recurrent venous thromboembolism at 3 months' follow‐up." data-id="CD001100-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 LMWH versus UFH in people with venous thromboembolism, outcome: 1.4 Incidence of recurrent venous thromboembolism at 3 months' follow‐up. </p> </div> </div> </div> <div class="figure" id="CD001100-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 LMWH versus UFH in people with venous thromboembolism, outcome: 1.6 Reduction in thrombus size (pre‐ and post‐treatment venograms)." data-id="CD001100-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 LMWH versus UFH in people with venous thromboembolism, outcome: 1.6 Reduction in thrombus size (pre‐ and post‐treatment venograms). </p> </div> </div> </div> </section> <section id="CD001100-sec-0080"> <h3 class="title" id="CD001100-sec-0080">Potential biases in the review process</h3> <p>Neither of the authors of this review was involved in any of the included or excluded studies. Furthermore, neither has any commercial or other conflict of interest. The search was as comprehensive as possible; and the two review authors independently assessed all studies for inclusion. We are confident that we have included all relevant studies and we have attempted to reduce bias in the review process by performing data extraction and assessing study quality independently. However, the possibility remains that we may have missed studies which have not been published. </p> <p>The original review did not set out to use the ISTH bleeding definition. However, given that this is now the standard accepted definition for major bleeding, we performed a post hoc sensitivity analysis for ISTH bleeding definitions in order to assess the effect of bleeding definitions used. The results from this sensitivity analysis (<a href="./references#CD001100-fig-0039" title="">Analysis 9.1</a>) are similar to the results from the analysis including all studies (<a href="./references#CD001100-fig-0012" title="">Analysis 1.7</a>) irrespective of their definition of major and clinically relevant bleeding. </p> </section> <section id="CD001100-sec-0081"> <h3 class="title" id="CD001100-sec-0081">Agreements and disagreements with other studies or reviews</h3> <p>One network meta‐analysis of four studies compared three LMWH preparations (tinzaparin, nadroparin and enoxaparin) in terms of safety and efficacy for the treatment of deep vein thrombosis (<a href="./references#CD001100-bbs2-0060" title="DiazJP , Soto MolinaH , MarquezM , Escobar JuarezY . Low‐molecular‐weight heparin in treatment of deep‐vein thrombosis: A network meta‐analysis. Value in Health2015;18(3):A31. ">Diaz 2015</a>). Authors found no evidence of differences between tinzaparin, nadroparin and enoxaparin for recurrence of DVT and major bleeding. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001100-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001100-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/full#CD001100-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001100-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/full#CD001100-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 LMWH versus UFH in people with venous thromboembolism, outcome: 1.1 Incidence of recurrent venous thromboembolism during initial treatment." data-id="CD001100-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 LMWH versus UFH in people with venous thromboembolism, outcome: 1.1 Incidence of recurrent venous thromboembolism during initial treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/full#CD001100-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 LMWH versus UFH in people with venous thromboembolism, outcome: 1.4 Incidence of recurrent venous thromboembolism at 3 months' follow‐up." data-id="CD001100-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 LMWH versus UFH in people with venous thromboembolism, outcome: 1.4 Incidence of recurrent venous thromboembolism at 3 months' follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/full#CD001100-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 LMWH versus UFH in people with venous thromboembolism, outcome: 1.6 Reduction in thrombus size (pre‐ and post‐treatment venograms)." data-id="CD001100-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 LMWH versus UFH in people with venous thromboembolism, outcome: 1.6 Reduction in thrombus size (pre‐ and post‐treatment venograms). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/full#CD001100-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 1 Incidence of recurrent venous thromboembolism during initial treatment." data-id="CD001100-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 1 Incidence of recurrent venous thromboembolism during initial treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 2 Incidence of recurrent venous thromboembolism at the end of follow‐up." data-id="CD001100-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 2 Incidence of recurrent venous thromboembolism at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 3 Incidence of recurrent venous thromboembolism at 1 month follow‐up." data-id="CD001100-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 3 Incidence of recurrent venous thromboembolism at 1 month follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 4 Incidence of recurrent venous thromboembolism at 3 months' follow‐up." data-id="CD001100-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 4 Incidence of recurrent venous thromboembolism at 3 months' follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 5 Incidence of recurrent venous thromboembolism at 6 months' follow‐up." data-id="CD001100-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 5 Incidence of recurrent venous thromboembolism at 6 months' follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-001-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 6 Reduction in thrombus size (pre‐ and post‐treatment venograms)." data-id="CD001100-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 6 Reduction in thrombus size (pre‐ and post‐treatment venograms). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 7 Incidence of major haemorrhagic episodes (during initial treatment)." data-id="CD001100-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 7 Incidence of major haemorrhagic episodes (during initial treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 8 Overall mortality at the end of follow‐up." data-id="CD001100-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 LMWH versus UFH in patients with venous thromboembolism, Outcome 8 Overall mortality at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis, Outcome 1 Incidence of recurrent venous thromboembolism at the end of follow‐up." data-id="CD001100-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis, Outcome 1 Incidence of recurrent venous thromboembolism at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis, Outcome 2 Incidence of recurrent deep venous thrombosis at the end of follow‐up." data-id="CD001100-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis, Outcome 2 Incidence of recurrent deep venous thrombosis at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis, Outcome 3 Incidence of pulmonary embolism at the end of follow‐up." data-id="CD001100-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis, Outcome 3 Incidence of pulmonary embolism at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis, Outcome 4 Reduction in thrombus size (pre‐ and post‐treatment venograms)." data-id="CD001100-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis, Outcome 4 Reduction in thrombus size (pre‐ and post‐treatment venograms). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis, Outcome 5 Incidence of major haemorrhagic episodes (during initial treatment)." data-id="CD001100-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis, Outcome 5 Incidence of major haemorrhagic episodes (during initial treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis, Outcome 6 Overall mortality at the end of follow‐up." data-id="CD001100-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 LMWH versus UFH in patients with proximal deep venous thrombosis, Outcome 6 Overall mortality at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 LMWH versus UFH in patients with pulmonary embolism, Outcome 1 Incidence of recurrent venous thromboembolism at the end of follow‐up." data-id="CD001100-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 LMWH versus UFH in patients with pulmonary embolism, Outcome 1 Incidence of recurrent venous thromboembolism at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 LMWH versus UFH in patients with pulmonary embolism, Outcome 2 Reduction in thrombus size (pre‐ and post‐treatment venograms)." data-id="CD001100-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 LMWH versus UFH in patients with pulmonary embolism, Outcome 2 Reduction in thrombus size (pre‐ and post‐treatment venograms). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 LMWH versus UFH in patients with pulmonary embolism, Outcome 3 Mean change in pulmonary vascular obstruction severity score." data-id="CD001100-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 LMWH versus UFH in patients with pulmonary embolism, Outcome 3 Mean change in pulmonary vascular obstruction severity score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 LMWH versus UFH in patients with pulmonary embolism, Outcome 4 Incidence of major haemorrhagic episodes (during initial treatment)." data-id="CD001100-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 LMWH versus UFH in patients with pulmonary embolism, Outcome 4 Incidence of major haemorrhagic episodes (during initial treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 LMWH versus UFH in patients with pulmonary embolism, Outcome 5 Overall mortality at end of follow‐up." data-id="CD001100-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 LMWH versus UFH in patients with pulmonary embolism, Outcome 5 Overall mortality at end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 LMWH versus UFH in patients with venous thromboembolism and malignant disease, Outcome 1 Mortality at the end of follow‐up." data-id="CD001100-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 LMWH versus UFH in patients with venous thromboembolism and malignant disease, Outcome 1 Mortality at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 LMWH versus UFH in patients with venous thromboembolism without malignant disease, Outcome 1 Mortality at the end of follow‐up." data-id="CD001100-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 LMWH versus UFH in patients with venous thromboembolism without malignant disease, Outcome 1 Mortality at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 LMWH versus subcutaneous UFH in patients with venous thromboembolism, Outcome 1 Incidence of recurrent venous thromboembolism at the end of follow‐up." data-id="CD001100-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 LMWH versus subcutaneous UFH in patients with venous thromboembolism, Outcome 1 Incidence of recurrent venous thromboembolism at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 LMWH versus subcutaneous UFH in patients with venous thromboembolism, Outcome 2 Incidence of major haemorrhagic episodes (during initial treatment)." data-id="CD001100-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 LMWH versus subcutaneous UFH in patients with venous thromboembolism, Outcome 2 Incidence of major haemorrhagic episodes (during initial treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 LMWH versus subcutaneous UFH in patients with venous thromboembolism, Outcome 3 Overall mortality at the end of follow‐up." data-id="CD001100-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 LMWH versus subcutaneous UFH in patients with venous thromboembolism, Outcome 3 Overall mortality at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 LMWH versus intravenous UFH in patients with venous thromboembolism, Outcome 1 Incidence of recurrent venous thromboembolism at the end of follow‐up." data-id="CD001100-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 LMWH versus intravenous UFH in patients with venous thromboembolism, Outcome 1 Incidence of recurrent venous thromboembolism at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 LMWH versus intravenous UFH in patients with venous thromboembolism, Outcome 2 Incidence of major haemorrhagic episodes (during initial treatment)." data-id="CD001100-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 LMWH versus intravenous UFH in patients with venous thromboembolism, Outcome 2 Incidence of major haemorrhagic episodes (during initial treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 LMWH versus intravenous UFH in patients with venous thromboembolism, Outcome 3 Overall mortality at the end of follow‐up." data-id="CD001100-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 LMWH versus intravenous UFH in patients with venous thromboembolism, Outcome 3 Overall mortality at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation, Outcome 1 Incidence of recurrent venous thromboembolism during initial treatment." data-id="CD001100-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation, Outcome 1 Incidence of recurrent venous thromboembolism during initial treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation, Outcome 2 Incidence of recurrent venous thromboembolism at the end of follow‐up." data-id="CD001100-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation, Outcome 2 Incidence of recurrent venous thromboembolism at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation, Outcome 3 Incidence of recurrent venous thromboembolism at 3 months' follow‐up." data-id="CD001100-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation, Outcome 3 Incidence of recurrent venous thromboembolism at 3 months' follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation, Outcome 4 Reduction in thrombus size (pre‐ and post‐treatment venograms)." data-id="CD001100-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation, Outcome 4 Reduction in thrombus size (pre‐ and post‐treatment venograms). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation, Outcome 5 Incidence of major haemorrhagic episodes (during initial treatment)." data-id="CD001100-fig-0037" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation, Outcome 5 Incidence of major haemorrhagic episodes (during initial treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation, Outcome 6 Overall mortality at the end of follow‐up." data-id="CD001100-fig-0038" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation, Outcome 6 Overall mortality at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 LMWH versus UFH: all randomised controlled trials that used ISTH definition of major bleeding, Outcome 1 Incidence of major haemorrhagic episodes (during initial treatment)." data-id="CD001100-fig-0039" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 LMWH versus UFH: all randomised controlled trials that used ISTH definition of major bleeding, Outcome 1 Incidence of major haemorrhagic episodes (during initial treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 LMWH versus UFH by year of publication, Outcome 1 Incidence of recurrent venous thromboembolism during initial treatment." data-id="CD001100-fig-0040" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 LMWH versus UFH by year of publication, Outcome 1 Incidence of recurrent venous thromboembolism during initial treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 LMWH versus UFH by year of publication, Outcome 2 Incidence of recurrent venous thromboembolism at the end of follow‐up." data-id="CD001100-fig-0041" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 LMWH versus UFH by year of publication, Outcome 2 Incidence of recurrent venous thromboembolism at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 LMWH versus UFH by year of publication, Outcome 3 Incidence of major haemorrhagic episodes (during initial treatment)." data-id="CD001100-fig-0042" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 LMWH versus UFH by year of publication, Outcome 3 Incidence of major haemorrhagic episodes (during initial treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001100-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/urn:x-wiley:14651858:media:CD001100:CD001100-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_t/tCD001100-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 LMWH versus UFH by year of publication, Outcome 4 Overall mortality at the end of follow‐up." data-id="CD001100-fig-0043" src="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 LMWH versus UFH by year of publication, Outcome 4 Overall mortality at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/media/CDSR/CD001100/image_n/nCD001100-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001100-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">LMWH compared to UFH for initial treatment of venous thromboembolism</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>LMWH compared to UFH for initial treatment of venous thromboembolism</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with venous thromboembolism (VTE)<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> Low molecular weight heparin (LMWH)<br/> <b>Comparison:</b> Unfractionated heparin (UFH) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with UFH</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with LMWH</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of recurrent VTE<sup>1</sup> after </p> <p>initial treatment (up to 15 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.69<br/> (0.49 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6238<br/> (18 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000<br/> (12 to 24) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of recurrent VTE<sup>1</sup> </p> <p>(3 months follow‐up)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>OR 0.71<br/> (0.56 to 0.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>6661<br/> (16 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>51 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>37 per 1000<br/> (29 to 46) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of recurrent VTE<sup>1</sup> </p> <p>(end of follow‐up)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.72<br/> (0.59 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9489<br/> (22 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/> (30 to 44) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Reduction in thrombus size</p> <p>(pre‐ and post‐treatment venograms) <sup>5</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.71<br/> (0.61 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2909<br/> (16 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> LOW <sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>423 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>342 per 1000<br/> (309 to 375) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of major haemorrhagic episodes</p> <p>(during initial treatment ‐ up to 15 days) <sup>7</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.69<br/> (0.50 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8780<br/> (25 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/> (11 to 20) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall mortality</p> <p>(end of follow‐up)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.84<br/> (0.70 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9663<br/> (24 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000<br/> (41 to 57) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> for 'study population' was the average risk in the comparison groups (i.e. total number of participants with events in the control group divided by the number of participants in the comparison group). <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>LMWH</b> ; low molecular weight heparin; <b>RCTs</b> ; randomised controlled trials <b>OR:</b> Peto odds ratio; <b>UFH</b> : unfractionated heparin; <b>VTE</b>: venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Recurrent venous thromboembolism (VTE) defined as recurrent deep vein thrombosis (DVT) or recurrent pulmonary embolism (PE). The diagnosis of recurrent DVT was accepted if one of the following criteria was met: (a) a new, constant intraluminal‐filling defect not present on the last available venogram; (b) if the venogram was not diagnostic either an abnormal 125I‐fibrinogen leg scan or abnormal impedance plethysmogram or ultrasound result, which had been normal before the suspected recurrent episode (<a href="./references#CD001100-bbs2-0057" title="BullerHR , LensingAWA , HirshJ , tenCateJW . Deep venous thrombosis: new noninvasive tests. Thrombosis and Haemostasis1991;66(1):133‐9. ">Buller 1991</a>). The diagnosis of PE was accepted if one of the following criteria was met: (a) a segmental defect on the perfusion lung scan that was unmatched on the ventilation scan or chest roentgenogram; (b) positive pulmonary angiography; (c) PE at autopsy.<br/> <sup>2</sup> Downgraded as risk of bias serious due to high risk of attrition bias in 4 studies (<a href="./references#CD001100-bbs2-0006" title="FiessingerJN , FernandezML , GattererE , OhlssonCG . Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial. Haemostasis1994;24(Suppl 1):Abstract 44. FiessingerJN , Lopez‐FernandezM , GattererE , GranqvistS , KherA , OlssonCG , et al. Once‐daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1996;76(2):195‐9. ">Fiessinger 1996</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0022" title="NinetJ , BachetP , PrandoniP , RuolA , VigoM , BarretA , et al. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1991;65(3):251‐6. ">Ninet 1991</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>), high risk of reporting bias in 2 studies (<a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>) and high risk of other bias in 3 studies (<a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>).<br/> <sup>3</sup> Downgraded as risk of bias serious due to high risk of attrition bias in 1 study (<a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>), high risk of reporting bias in one study (<a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>), and high risk of other bias in 2 studies (<a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>).<br/> <sup>4</sup> Downgraded as risk of bias serious due to high risk of attrition bias in 2 studies (<a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>), high risk of reporting bias in 2 studies (<a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>), and high risk of other bias in 3 studies (<a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>)<br/> <sup>5</sup> The number of participants in each group with an improved venographic score, if pre‐ and post‐treatment venograms were obtained and were assessed by persons unaware of treatment assignment.<br/> <sup>6</sup> Downgraded as risk of bias serious due to high risk of selection bias in 1 study (<a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>), high risk of attrition bias in 6 studies (<a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>; <a href="./references#CD001100-bbs2-0006" title="FiessingerJN , FernandezML , GattererE , OhlssonCG . Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial. Haemostasis1994;24(Suppl 1):Abstract 44. FiessingerJN , Lopez‐FernandezM , GattererE , GranqvistS , KherA , OlssonCG , et al. Once‐daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1996;76(2):195‐9. ">Fiessinger 1996</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0022" title="NinetJ , BachetP , PrandoniP , RuolA , VigoM , BarretA , et al. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1991;65(3):251‐6. ">Ninet 1991</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>), high risk of reporting bias in 1 study (<a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>), and high risk of other bias in 4 studies (<a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>). Downgraded further due to moderate heterogeneity (I² = 56%)<br/> <sup>7</sup> Haemorrhages were classified as major if they were intracranial, retroperitoneal, led directly to death, necessitated transfusion or they led to the interruption of antithrombotic treatment or (re)operation.<br/> <sup>8</sup> Downgraded as risk of bias serious due to high risk of selection bias in 1 study (<a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>), high risk of attrition bias in 5 studies (<a href="./references#CD001100-bbs2-0006" title="FiessingerJN , FernandezML , GattererE , OhlssonCG . Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial. Haemostasis1994;24(Suppl 1):Abstract 44. FiessingerJN , Lopez‐FernandezM , GattererE , GranqvistS , KherA , OlssonCG , et al. Once‐daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1996;76(2):195‐9. ">Fiessinger 1996</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0022" title="NinetJ , BachetP , PrandoniP , RuolA , VigoM , BarretA , et al. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1991;65(3):251‐6. ">Ninet 1991</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>), high risk of reporting bias in 2 studies (<a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>), and high risk of other bias in 5 studies (<a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>).<br/> <sup>9</sup> Downgraded as risk of bias serious due to high risk of selection bias in 1 study (<a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>), high risk of attrition bias in 4 studies (<a href="./references#CD001100-bbs2-0002" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV . Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. ">Breddin 2001</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0029" title="TheryC , SimonneauG , MeyerG , HelenonO , BrideyF , ArmagnacC , et al. Randomized trial of subcutaneous low‐molecular‐weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation1992;85(4):1380‐9. ">Thery 1992</a>), high risk of reporting bias in 2 studies (<a href="./references#CD001100-bbs2-0016" title="HolmstromM , LindmarkerP , GranqvistS , JohnssonH , LocknerD . A 6‐month venographic follow‐up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis1997;78(2):803‐7. LindmarkerP , HolmstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once‐daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis1994;72(2):186‐90. ">Lindmarker 1994</a>; <a href="./references#CD001100-bbs2-0023" title="Pérez de LlanoLA , Baloira VillarA , Veres RacamondeA , VeigaF , Golpe , GomezR , et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia2003;39(8):341‐5. ">Pérez de Llano 2003</a>), and high risk of other bias in 5 studies (<a href="./references#CD001100-bbs2-0007" title="FindikS , ErkanML , SelçukMB , AlbayrakS , AticiAG , DoruF . Low‐molecular‐weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration2002;69(5):440‐4. ">Findik 2002</a>; <a href="./references#CD001100-bbs2-0009" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed‐dose, body weight‐independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652‐6. ">Harenberg 2000a</a>; <a href="./references#CD001100-bbs2-0011" title="KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and long‐term treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD001100-bbs2-0017" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14‐8. ">Lopaciuk 1992</a>; <a href="./references#CD001100-bbs2-0018" title="Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis1994;24(Suppl 1):Abstract 248. LuomanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC , et al. A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85‐92. ">Luomanmaki 1996</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">LMWH compared to UFH for initial treatment of venous thromboembolism</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/full#CD001100-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001100-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">LMWH versus UFH in patients with venous thromboembolism</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent venous thromboembolism during initial treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.49, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.20, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.26, 8.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.27, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Dalteparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.07, 17.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.52, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Certoparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.35, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of recurrent venous thromboembolism at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.59, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.49, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.41, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Ardeparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.00, 6.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2043</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.49, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Dalteparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.42, 7.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.44, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Certoparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.40, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Incidence of recurrent venous thromboembolism at 1 month follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1741</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.56, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.10, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.24, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.64, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Incidence of recurrent venous thromboembolism at 3 months' follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.56, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.49, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.26, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2043</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.49, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Dalteparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.44, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Incidence of recurrent venous thromboembolism at 6 months' follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.48, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.37, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Dalteparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.42, 7.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Certoparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.40, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Reduction in thrombus size (pre‐ and post‐treatment venograms) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.61, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.50, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Ardeparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.14, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.17, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Dalteparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.90, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 CY 222 versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.32, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.43, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Certoparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.50, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 Bemiparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.24, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Incidence of major haemorrhagic episodes (during initial treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.50, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.19, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.41, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.54, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Dalteparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.02, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 CY 222 versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.49, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 Certoparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.25, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8 Bemiparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.39 [0.46, 118.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Overall mortality at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.70, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.48, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.69, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Ardeparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2043</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.64, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Dalteparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.13, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.59, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 Certoparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.36, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 Bemiparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.13, 6.90]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">LMWH versus UFH in patients with venous thromboembolism</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001100-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">LMWH versus UFH in patients with proximal deep venous thrombosis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent venous thromboembolism at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.44, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.44, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.17, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.32, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.15, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Certoparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.40, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Bemiparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of recurrent deep venous thrombosis at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.41, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.41, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.12, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.34, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.17, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Bemiparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Incidence of pulmonary embolism at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3024</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.28, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.27, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.14, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.05, 5.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.10, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Certoparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.11, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Bemiparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [0.20, 18.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Reduction in thrombus size (pre‐ and post‐treatment venograms) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.27, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Bemiparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.24, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Dalteparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.22, 9.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Incidence of major haemorrhagic episodes (during initial treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.29, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.09, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.06, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.42, 6.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Certoparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.26, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Overall mortality at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.47, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.38, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.23, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.37, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.32, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Certoparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.30, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Bemiparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.13, 6.90]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">LMWH versus UFH in patients with proximal deep venous thrombosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001100-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">LMWH versus UFH in patients with pulmonary embolism</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent venous thromboembolism at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.50, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.26, 2.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.37, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Dalteparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.35, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Reduction in thrombus size (pre‐ and post‐treatment venograms) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.23, 8.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.53 [0.32, 95.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Dalteparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.05, 5.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean change in pulmonary vascular obstruction severity score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.14 [‐4.39, ‐1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.28 [‐4.55, ‐2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Dalteparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐5.94, 7.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Incidence of major haemorrhagic episodes (during initial treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.04, 4.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.01, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.61 [0.11, 297.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Dalteparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Overall mortality at end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.17, 16.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.06, 15.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.61 [0.11, 297.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Dalteparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">LMWH versus UFH in patients with pulmonary embolism</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001100-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">LMWH versus UFH in patients with venous thromboembolism and malignant disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Mortality in patients with malignant disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.33, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Mortality in patients with malignant disease in trial with adequate concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.31, 0.82]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">LMWH versus UFH in patients with venous thromboembolism and malignant disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001100-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">LMWH versus UFH in patients with venous thromboembolism without malignant disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Mortality in patients without malignant disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.61, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Mortality in patients without malignant disease in trials with adequate concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.62, 1.62]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">LMWH versus UFH in patients with venous thromboembolism without malignant disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001100-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">LMWH versus subcutaneous UFH in patients with venous thromboembolism</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent venous thromboembolism at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.56, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of major haemorrhagic episodes (during initial treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.50, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Overall mortality at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.91, 2.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">LMWH versus subcutaneous UFH in patients with venous thromboembolism</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001100-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">LMWH versus intravenous UFH in patients with venous thromboembolism</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent venous thromboembolism at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.56, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of major haemorrhagic episodes (during initial treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.43, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Overall mortality at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.63, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">LMWH versus intravenous UFH in patients with venous thromboembolism</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001100-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent venous thromboembolism during initial treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.50, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.18, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.26, 8.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.24, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.52, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Certoparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.40, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of recurrent venous thromboembolism at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.60, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.45, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.26, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Ardeparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.00, 6.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1934</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.51, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.62, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Certoparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1469</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.42, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Incidence of recurrent venous thromboembolism at 3 months' follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.60, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.44, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.26, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1934</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.51, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.62, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Reduction in thrombus size (pre‐ and post‐treatment venograms) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.37, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.31, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Ardeparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.14, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Enoxparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.17, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Certoparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.38, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Incidence of major haemorrhagic episodes (during initial treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.45, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.18, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.12, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.50, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.49, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Certoparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.24, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Overall mortality at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.65, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.47, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.37, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Ardeparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1934</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.63, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.57, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Certoparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1469</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.38, 1.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">LMWH versus UFH: all randomised controlled trials with adequate concealment of allocation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001100-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">LMWH versus UFH: all randomised controlled trials that used ISTH definition of major bleeding</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of major haemorrhagic episodes (during initial treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.52, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Nadroparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.19, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Tinzaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.41, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Enoxaparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.54, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Dalteparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.02, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Reviparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.49, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Certoparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.25, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Bemiparin versus unfractionated heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.39 [0.46, 118.89]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">LMWH versus UFH: all randomised controlled trials that used ISTH definition of major bleeding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001100-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">LMWH versus UFH by year of publication</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent venous thromboembolism during initial treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.49, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of recurrent venous thromboembolism at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.59, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Incidence of major haemorrhagic episodes (during initial treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8790</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.51, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Overall mortality at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.70, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">LMWH versus UFH by year of publication</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001100.pub4/references#CD001100-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001100.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001100-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001100-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD001100-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD001100-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001100-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001100\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001100\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001100\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001100\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001100\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001100\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001100\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001100\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001100\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001100\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001100\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001100\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001100\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001100\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001100\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001100\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001100\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001100\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001100.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001100.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001100.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001100.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001100.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715953134"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001100.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715953137"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001100.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d93ab3c689368',t:'MTc0MDcxNTk1My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 